

## CURRICULUM VITAE

### Shlomo Melmed, M.D.

**Office Address:** Academic Affairs  
Cedars-Sinai Medical Center  
8700 Beverly Blvd., 2015  
Los Angeles, CA 90048  
Tel (310) 423-4691, Fax (310) 423-0119  
E-mail address: [melmed@csmc.edu](mailto:melmed@csmc.edu)

**Clinic:** Pituitary Center  
127 S. San Vicente Blvd.  
# A6600 (AHSP)  
Los Angeles, CA 90048  
Tel 310 423-2830  
Fax (310) 423-2819

**Date of Birth** July 8, 1948  
**Place of Birth** Cape Town, South Africa  
**Citizenship** U.S.A.

#### MEDICAL EDUCATION

University of Cape Town School of Medicine, South Africa 1965 - 1970  
Received Degree M. B. Ch. B with Distinction; Gold Medal in Medicine and Pediatrics

#### POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS

Intern & Resident, Internal Medicine  
and Endocrinology, Sheba Medical Center, Israel 1971 - 1977  
Endocrinology Research Fellow, 1978 - 1980  
Wadsworth VA Medical Center, UCLA School of Medicine

#### LICENSURE AND SPECIALTY CERTIFICATIONS

California, #34247  
**Diplomate:** American Board of Internal Medicine 1979  
**Diplomate:** Endocrinology & Metabolism Subspecialty 1983

#### FACULTY APPOINTMENTS

##### Cedars-Sinai Medical Center, Los Angeles, CA:

Dean of the Medical Faculty and Executive Vice President 2008 - Current  
Chief Academic Officer 1998 - Current  
Director, Cedars-Sinai Research Institute 1992 - Current  
Director, Division of Endocrinology & Metabolism 1986 - 1998  
Associate Director, Cedars-Sinai Research Institute 1988 - 1991  
Associate Director, Division of Endocrinology 1983 - 1986  
Laboratory Instructor, Dept. Physiology, University of Cape Town 1967

##### University of California at Los Angeles, School of Medicine:

Associate Dean 1998 - Current  
Professor of Medicine 1988 - Current  
Associate Professor of Medicine 1984 - 1988  
Assistant Professor of Medicine 1980 - 1984  
Visiting Assistant Professor of Medicine 1979 - 1980

#### PROFESSIONAL ACTIVITIES

##### Editorial

*Editor-in-Chief:* Endocrine Updates 1998 - 2012  
*Editor-in-Chief:* Endocrinology 1992 - 1997

<i>Editor:</i>	Clinical Endocrinology	1998
<i>Editor:</i>	Endocrinology	1990 – 1992
<i>Editor:</i>	Frontiers in Pituitary Endocrinology	2010 - Current
<i>Editor (Endocrine):</i>	Encyclopedia of Human Biology (3 <sup>rd</sup> Edition)	2010 – 2014
<i>Consulting Editor:</i>	Journal of Clinical Investigation	1992 – Current
<i>Editor-in-Chief:</i>	Pituitary	1998 - Current

*Editorial Board:*

Endocrinology	1984 - 1988
Peptide Therapy	1989 - 1995
Journal Clinical Endocrinology & Metabolism	1998 - 2001
Endocrine Reviews	2003 - 2006
Faculty of 1000 Medicine	2004 - 2010
Section Head for Neuro-endocrinology and Pituitary	
Nature Clinical Practice Endocrinology and Metabolism	2005 - 2010
Expert Review of Endocrinol and Metab	2006 - 2010
Endocrine Pathology	1989
Journal of Endocrinology and Journal of Molecular Endocrinology (Joint Editorial Board)	2011 - 2012
Endocrine-Related Cancer	2002 – 2010
Bailliere’s Best Practice & Research in Clinical Endocrinology and Metabolism	1999 - Current
Endocrine Today, Clinical News on Diabetes and Endocrine Disorders	2007 - Current
Clinical and Translational Science (CTS)	2008 - Current
Nature Reviews Endocrinology	2010 – Current

**REVIEWER** Journal of Clinical Investigation, Journal of Biological Chemistry; Molecular Endocrinology, Nature, New England Journal of Medicine; PNAS; Nature Medicine, Science; Annals of Internal Medicine; JAMA.

**GRANT REVIEWER**

NIH, Endocrinology Study Section 1991; 1996-2000; 2009; 2012  
 NIH, Chairperson, Special Endocrinology Study Sections 1990; 1995  
 NIH, Biomedical Sciences and NIDDK Study Sections (ad hoc) 1988-1989; 1994; 2009; 2011-2012  
 Wellcome Foundation, UK; Medical Research Council, UK;  
 National Science Foundation; VA Merit Review; US-Israel Binational Foundation; American Diabetes Association, California; The Ares-Serono Foundation; French National Research Agency (ANR)

**SERVICE**

*Cedars-Sinai Health System*

Executive Committee of the Board	1998 - Current
President’s Executive Advisory Committee	1998 - Current
Executive Management Group	1998 - Current
Research Institute Advisory Committee (Chair)	1992 – 1998
Resource Development Committee	1998 - Current
Community Benefit Committee	2000 - 2001

Quality Assurance Committee & Executive Committee	1986 - 1989
Medicine Advisory Committee	1986 - 1998
Medical Policy Committee	2000 - Current
Housestaff Clinical Competency Committee	1986 - 1995
Strategic Planning Task Force & President's Council	1990 – Current
Medical Leadership Group (Chair)	1998- Current

*UCLA School of Medicine*

Appointments and Promotions Committee Department of Medicine	1986 - 1993
Committee on Education in the Medical Sciences	1989 - 1991
Legislative Assembly, UCLA Academic Senate	1987 - 1989
Search Committee, Brain Research Institute	1988
NICHD Population Research Center, Executive Committee	1987 - 1991
Committee on Endocrinology Curriculum Planning	1990 - 1992
Advisory Board, Center for Neurovisceral Sciences and Women's Health	2002 - 2007
Deans Education Council	1999 - Current
Task Force for LCME Accreditation 2004 - Current	
CTSI Steering Committee	2011 - Current

*American Diabetes Association*

Research Peer Review Committee-California, Chair	1983 - 1990
--	-------------

*American Thyroid Association*

Program Committee	1988
Finance and Audit Committee (Chair)	1988 - 1989

*Endocrine Society*

Council	1999 - 2003
Clinical Endocrinology Initiatives Committee	1988 - 1989
Postgraduate Committee	1990 - 1992
Subcommittee for Introduction to Endocrine Investigation Course	1990 - 1992
Journals Steering & Publications Committee	1992 - 1997
Program Committee, Postgraduate Assembly	1995
Review Committee for Travel Grants	1995; 2008
Planning Committee, Clinical Endocrinology Update	1999
Chair, Central Committee, (ISE) Endocrine Society	2000 - 2008
Self-Assessment Program on CD-ROM (Pituitary Faculty)	1998
Clinical Guidelines Subcommittee	2007 – 2010
Endocrine Society Guideline Task Force Member	2011 – 2016

*International Society of Endocrinology*

Central Committee, Int'l Society of Endocrinology	1996 - 2004
Program Committee, International Congress of Endocrinology	2000
Chair, Program Committee, International Congress of Endocrinology	2004
President, International Society of Endocrinology	2004 – 2008
Co-Chair, International Congress of Endocrinology	2018

*AFCR/ASCI/AAP*

Western Soc Clinical Investigation, Endocrinology Coordinator	1985, 1987
---	------------

Endocrinology and Metabolism Chairman, (AFCR/ASCI/AAP) Nominating Committee, WAP	1985, 1989, 1991 1992
<u>Los Angeles Cross-Town Endocrine Society</u> Chairperson	1984 - 1985
<u>Pituitary Society</u> President	2002
Executive Council (Founding Member)	1993 - Current
Program Committee (Co-Chair)	1994 - Current
Chair, International Pituitary Congress	1989, 1993
Co-Chair, International Pituitary Congress	1996 - Current
<u>National</u> Acromegaly Centennial Symposium, Co-Chair	1986
Recent Advances in Somatostatin Basic Research Co-Chair	1991
Gordon Research Conference (PRL) Organizing Committee	1996
Vice Chair and Chair, Gordon Research Conference (PRL)	2002, 2004
International Society for NeuroImmuno Modulation, Council	2000 - 2004
Board of Directors, Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP)	2001- 2006
Audit Committee (AAHRPP)	2003 - 2006
Accreditation Review Committee (AAHRPP)	2003 - 2006
USP Council of Experts – Endocrinology Expert Committee	1995 - 2005
Association of Patient Oriented Research (APOR) NIH Advocacy Committee	2005 - 2008
Board Member, California Institute of Regenerative Medicine Independent Citizen Oversight Committee (ICOC)	2010 – Current
Director, California Life Sciences Association Board	2014 – Current
Acromegaly Consensus Conference, Co-Chair	2000 - Current
Emulate, Inc. Board of Directors	2014 - Current
California Life Sciences Association, Board of Directors	2015 – Current

#### **MEMBERSHIPS IN SCHOLARLY SOCIETIES**

Association of American Physicians (elected)  
American Society of Clinical Investigation (elected)  
American Federation of Clinical Research  
Western Society of Clinical Investigation  
Western Association of Physicians  
Endocrine Society  
Royal Society of Medicine  
Pituitary Society (Founding member)

#### **CONSULTING ACTIVITIES**

AMA Drug Evaluations	1993 - 1995
ACP MKSAP Program	1993 - 1995
Pharmacia	1996 - 2001
Chair, GH Advisory Group, Eli Lilly, USA	1995 - 1997
Sensus Corporation	1995 - 2000
Chair, Acromegaly Advisory Group, Novartis	1996 - 2008
Henri Beaufor Institute	1997 - 2000
Current Drugs	1997
Access the Experts Acromegaly	2000 - 2002

Neurocrine	2001
Tercica	2006 - 2008
Quality Pharmaceutical Services (QPS)	2009 - 2010
Pfizer	2010
Global HYPOCCS Advisory Board, Eli Lilly	1995 - 2011
Ipsen Global	2009 - Current
Syntaxin	2009 - 2012
Genentech	2013
Chiasma Pharma	2009 - Current
Ionis	2010 - Current
Novartis Global	2010 - Current
Stonebridge	2016- Current
Ono Pharma	2016- Current
Midatech Pharma	2016-Current

#### **HONORS AND SPECIAL AWARDS**

America's Top Physicians	2014
Visiting Professorship Award in Growth Hormone (Endocrine Society)	2012
Pioneer in Medicine, Cedars-Sinai Medical Center	2011
Endocrine Regulation Prize, Fondation IPSEN	2010
Master of the American College of Physicians	2010
Transatlantic Medal (Society for Endocrinology)	2010
Pituitary Society Lifetime Achievement Award	2009
Fellow, Royal College of Physicians (Hon)	2007
Endocrine Society Clinical Investigator Award	2004
Honorary Professor, Fudan University, Shanghai	2004
Pituitary Society Award, Contributions to Understanding Pituitary Disease	1997
Honorary Member, German Endocrine Society	1996
Best Doctors in America	1994-Current
McGill University, Neuro-Endocrinology Award	1995
Royal Society of Medicine, Clinical Endocrinology Trust Medal	1994
Fellow of American College of Physicians	1981
NIAMDD Clinical Investigator Award, NIH	1981

#### **POST-DOCTORAL TRAINEES**

1. Shunichi Yamashita, M.D.	1984-1987
2. James Fagin, M.D.	1987-1991
3. John Ong, M.D.	1986-1987
4. Shigeki Morita, M.D.	1987-1989
5. Sarah Pixley, Ph.D.	1987-1989
6. Hironori Namba, M.D.	1989-1991
7. Sawsan Barakat, M.D.	1989-1991
8. Diane Prager, M.D.	1990-1993
9. Vivien Herman, M.D.	1987-1990
10. Hiro Yamasaki, M.D.	1990-1992
11. Keiichi Matsuo, M.D.	1990-1992
12. Rivka Gonsky, Ph.D.	1990-1993
13. Mathew Weber, M.D.	1992-1994
14. Shereen Ezzat, M.D.	1992-1994

15. Hiro Yamamoto, M.D.	1993-1995
16. Jonathan Webster, M.D., Ph.D.	1994-1996
17. Yona Greenman, M.D.	1994-1996
18. Lin Pei, M.D., Ph.D.	1994-1996
19. Hirofumi Takino, M.D.	1994-1996
20. Stephen Petersen, M.D.	1995-1996
21. Ilan Shimon, M.D.	1995-1997
22. Zhiyong Wang, Ph.D.	1996-2002
23. Sadanori Akita, M.D.	1995-1997
24. David Ray, M.D., Ph.D.	1995-1997
25. Xun Zhang, Ph.D.	1996-1998
26. Marlys Drange, M.D., Ph.D.	1996-1999
27. Alberto Valentini, M.D.	1996-1998
28. Hiroki Yano, M.D.	1996-1998
29. Masahiro Nakashima, M.D.	1996-1998
30. Anthony Heaney, M.D., Ph.D.	1997-2000
31. Chris Auernhammer, M.D.	1997-1999
32. Marcelo Perrone, Ph.D.	1998-1999
33. Pinar Kadioglu, M.D.	1998-1999
34. Maria Zatelli, M.D.	1998-2000
35. Vera Chesnokova, M.D.	1998-2000
36. Hiroki Ishikawa, M.D.	1999-2001
37. Chris McCabe, Ph.D.	1999
38. Ruchi Mathur, MD	1999-2000
39. Run Yu, M.D., Ph.D.	1999-2004
40. Hiralal Maheshwari, M.D.	1999-2003
41. Ana Valeria Barros De Castro, M.D., Ph.D.	2000-2002
42. Rula Abbud, MD, Ph.D.	2000-2005
43. Anat Ben-Shlomo, M.D.	2000-2005
44. Ichiro Takumi, M.D.	2000-2001
45. Kozo Akino, M.D.	2000-2001
46. Anastasia Kariagina, Ph.D.	2000-2003
47. Helen Turner, M.D.	2001
48. Robert Murray, M.D.	2001-2003
49. Ningai Liu, M.D., Ph.D.	2001-2003
50. Irina Miklovsy, PhD	2001-2004
51. Enrico Moro, Ph.D.	2002-2003
52. Merav Fraenkel, M.D.	2002-2004
53. Sergio Licalzi, Ph.D.	2002-2004
54. Martha Cruz-Soto, Ph.D.	2003-2006
55. Tami Rubinek, Ph.D.	2003-2006
56. Ines Donangelo, M.D., Ph.D.	2004-2007
57. George Vlotides, M.D., Ph.D.	2004-2008
58. Yunguang Tong, Ph.D.	2005-2009
59. Cuiqi Zhou, Ph.D.	2005-2009
60. Anna Gruszka, M.D., Ph.D.	2005-2007
61. Yen Hao Chen, Ph.D.	2006-2008
62. Hubina Erika, Ph.D.	2007-2008
63. Alexey Resnenko, Ph.D.	2007-2008

64. Odelia Cooper, MD	2007-2009
65. Weijiang Zhao, Ph.D.	2007-2009
66. Magdalena Uhart, M.D.	2008-2014
67. Hidenori Fukuoka M.D., Ph.D.	2008-2011
68. Yoel Toledano, M.D.	2008-2010
69. Maya Tobita Kano, M.D.	2010-2012
70. Alan Parsa, M.D.	2010-2012
71. Takako Araki, M.D.	2011-2016
72. Yuji Tani, MD, Ph.D.	2012-2013
73. Daniel Cuevas-Ramos, M.D.	2012-2013
74. Maria Victoria Recouvreaux, Ph.D.	2013-2016
75. Xiaohai Liu, MD	2013-2014
76. Masaaki Yamamoto, MD	2014-Current
77. Hiraku Kameda, MD	2015-Current
78. Yuan Ren, MD	2015-Current

#### **PRE-DOCTORAL TRAINEES**

Beatrice Stefana, M.Pharm	1995-1997
Elena Faccenda, M.S.	1995-1997
Anita Huttner, M.S.	1996
Corinne Bousquet, Ph.D. (Doctoral)	1996-2000
Gregg Horwitz, Ph.D. (Masters)	1998-2001
Kolja Wawrowsky, Ph.D. (Doctoral)	2004-2007
Tamar Eigler, Ph.D. (Doctoral)	2010-2013

#### **INDIVIDUAL TRAINING FUNDING & AWARDS**

<i>James Fagin, (P. I.)</i>	1985 - 1987
NRSA Individual Training Award (NIADDK)	
American Thyroid Association Travel Award	1986
NIH, FIRST Award	1989 – 1994
<i>Sarah Pixley, NIH Summer Trainee Award</i>	1986
<i>Shunichi Yamashita, (P. I.)</i>	1986 – 1988
ADA Research Fellowship Award	
Research Trainee Award, Crosstown Endocrine Club	1985
International Thyroid Association, Travel Award	
WSCI Outstanding Trainee Award	1986 – 1987
Dean of Graduate School of Biomedical Sciences Nagasaki University School of Medicine	
<i>John Ong, WSCI Outstanding Trainee Award</i>	1988
<i>Diane Prager, (P. I.)</i>	1988 - 1990
ADA Research Fellowship Award	
WSCI Outstanding Trainee Award	1988
Crosstown Endocrine Club	
AFCR Trainee Award (National)	1989
Solomon Scholar Trainee Research Award	1990
NIDDK Clinical Investigator Award	1991 – 1996
<i>Shereen Ezzat, American Thyroid Association Travel Award</i>	1989
<i>Hiro Yamasaki, WSCI Outstanding Endocrinology Trainee</i>	1989
<i>Vivien Herman-Bonert, NIH Clinical Investigator Award</i>	1991 – 1996

<i>Lin Pei</i> , AFCR Trainee Award (National)	1995
Endocrine Society Travel Award	1996
NIH Clinical Investigator Award	1995 – 2001
<i>Ted Friedman</i> , NIDA New Investigator Award	1995 – 2000
Culpeper Award	1996 – 1998
<i>Masahiro Nakashima</i>	1996 – 1998
Professor and Head of Dept of Tumor and Diagnostic Pathology	
Nagasaki University	
<i>Ilan Shimon</i> , Merck Senior Fellowship Award, Endocrine Society	1997
<i>David Ray</i> , Endocrine Fellows Foundation Award	1997
<i>Chris Auernhammer</i> , Merck Senior Fellowship Award,	1998
Endocrine Society	
<i>Marlys Drange</i> , American College of Physicians,	1997
Regional Scientific Trainee Award;	1998
Endocrine Fellows Foundation Award	
<i>Tony Heaney</i> , Endocrine Fellows Foundation Award	1998
Fullbright Scholarship Award	1999
Merck Senior Fellowship Award, Endocrine Society	1999
Chancellor's Award, UCLA Postdoctoral Program	2000
International Cardura Competitive Awards, Pfizer	2001
<i>Gregory A. Horwitz</i> , Introduction to Molecular & Cellular	1999
Research, Travel Grant Award	
Endocrine Society Travel Grant Award	2000
Novartis Junior Investigator Award	2000
<i>Run Yu</i> , Endocrine Society Trainee Award	2000
Lilly Pituitary Scholars Fellowship, Endocrine Society	2001
NIH Clin Investigator Award (K08)	2005-2010
<i>Ning-Ai Liu</i> , 2 <sup>nd</sup> Annual Pfizer Scholars in Endocrinology	2003
Grant Program	
Clinical Investigator Award (K08 NIH)	2003-2008
DERC Pilot and Feasibility Grant (UCSD/UCLA)	2010-2011
<i>Cuiqi Zhou</i> , Travel Grant Award, Endocrine Society	2008
<i>Odelia Cooper</i> , NIH (K23) Mentored Patient Oriented Research Award	2009-2014
<i>Hidenori Fukuoka</i> , Travel Grant Award, Endocrine Society	2010
<i>Yunguang Tong</i> , NIH Award (K99)	2010-2015
<i>Hidenori Fukuoka</i> , Presidential Competitive and Travel Grant Award,	2010
Endocrine Society	
Young Investigator Award (YIA), Japan Endocrine Society	2011
Cuiqi Zhou, ASPIRE Young Investigator Competitive Grant Research	2014
Award (Pfizer)	

**CURRENT FUNDING:**

**Ongoing Research Support:**

**NIH/NIDDK R21DK103198 (Melmed PI) 06/01/2014-05/31/2017**

Title: Treatment of pituitary Cushing disease with selective CDK inhibitor, R-roscovitine

The goal of this project it to test a new and unique intervention directly targeting corticotroph tumors in patients with Cushing disease.

**NIH/NIDDK T32DK007770 (Melmed PI) 08/01/1999-06/30/2017**



Title: Institutional Training Program in Endocrinology, Diabetes, and Metabolism  
The goal of this project is to fund post-doctoral fellows in Endocrinology at Cedars-Sinai Medical Center.

**Pfizer, Inc. WS2036536 (Melmed PI) 10/01/2011-12/31/2017**  
Title: Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy and High Dose SRL + Weekly Pegvisomant Therapy  
The goal of this investigator-initiated project is to determine the most effective combination of somatostatin receptor ligand and GH receptor antagonist therapy in subjects with acromegaly at the lowest cost to patients.

**Doris Factor Endowed Molecular Endocrinology Laboratory (Melmed PI) 08/01/1989-12/31/2020**  
Title: Molecular mechanisms of hormone action in target cells and transgenic animals  
This permanently endowed laboratory funds research support for molecular endocrinology.

**Partnership for Health Analytic Research / Novartis (Bonert PI) 08/18/2014-08/17/2017**  
Title: The Burden of Illness in Patients with Cushing's Disease: A Retrospective Medical Chart Review  
This project aims to describe the comorbidities among Cushing's Disease patients and to describe treatment use and Cushing's Disease related healthcare utilization among patients.

**Cedars-Sinai Research Institute (Melmed PI) 09/01/2002-12/31/2020**  
Title: Pituitary Tumor Surveillance: Pathogenic Correlation  
This data/specimen registry aims to observe aspects of pituitary tumor recurrence and markers of persistent disease. The second goal of this database is to evaluate the long-term consequences of hormone replacement therapy for pituitary hormone insufficiency, as this is an independent risk factor for premature death.

**Pfizer ASPIRE Award in Pituitary Research (Melmed PI) 07/01/2016- 06/30/2018**  
Title: Mechanisms underlying colon neoplasia  
Studying transgenic models to determine role of GH in enabling colon mucosal neoplasia.

**INVITED LECTURES AND PRESENTATIONS (SELECTED):**

- 1986** • 38th Postgraduate Assembly of Endocrine Society, Los Angeles
- 1987** • 39th Postgraduate Assembly of Endocrine Society, San Francisco
- 1988** • UCSF, Peptidomimetic Therapy: A novel approach to endocrine and GI diseases
- 1989** • European Neuro-Endocrine Association, London (Plenary)  
• Baylor University, Peptidomimetic Therapy Symposium  
• Hospital of Good Samaritan, 11th Annual Endocrine Symposium  
• 2<sup>nd</sup> International Pituitary Congress, Palm Desert, CA
- 1990** • Pituitary Pathology Workshop, 4th Annual Meeting, Lyon, France  
• Endocrine Society, 42nd Postgraduate Assembly, Honolulu, Hawaii  
• University of Oregon Health Sciences, Portland  
The Nobel Wiley Jones Lectureship  
• University of Washington, Seattle  
Leonard Visiting Professor of Medicine
- 1991** • Endocrine Society: Introduction to Endocrine Investigation  
• Spanish Endocrine Society: Annual Mtg., Santiago (Plenary)  
• Somatostatin Meeting: Basic and Clinical Aspects, Monte Carlo  
• Sandostatin State-of-the-Art, Monte Carlo  
• 5th European Pituitary Workshop, Venice (Plenary)
- 1992** • Endocrine Society Ancillary Symposium: Diagnosis and medical management of hormone-secreting pituitary tumors, San Antonio  
• NY Academy of Sciences: Role of IGF-I in the nervous system, Arlington, VA

- Intl Symposium on GH II: Basic and clinical aspects, Tarpon Springs, Florida
- Somatostatin receptor imaging, Amsterdam, Netherlands
- Endocrine Society of Australia, Annual meeting, Ayers Rock, (Plenary)
- Garvin Institute of Medical Research, Sydney, Australia
- Third International Pituitary Congress, Los Angeles
- Sixth Prolactin Congress, Paris
- Israel Endocrine Society, Annual Mtg, Jerusalem (Plenary)
- 45th Postgraduate Assembly, Endocrine Society, San Francisco  
Workshop: Current Diagnosis and management of pituitary tumor
- Serono Symposia, , San Diego GHRH, GH and IGF-I: Basic and Clinical Advances
- Colorado Diabetes/Endocrine Institute, Aspen, Colorado
- Gordon Research Conference (Prolactin), Oxnard
- Harvard Medical School, Boston, Clinical Endocrinology Update
- Japan Endo Soc, Nagasaki Satellite Symp: Recent advances in Pituitary Research - Chair
- Japan Endocrine Society, Plenary
- Royal Society of Medicine, CERSM Visiting Professor at UK Med Schools
- 13th Joint Meeting of British Endocrine Societies (Plenary)
- British Growth Factor Group
- European Endocrine Society, Amsterdam
- McGill University Sandoz Neurendocrine Visiting Professor, Montreal
- Endocrine Society Meeting, Anaheim, Management of Acromegaly: A clinical Workshop
- Endocrine Society Annual Meeting Symposium on IGF-I, Invited Lecture
- Endocrine Nurses Society 4th Annual Symposium, California
- 
- State-of-the-Art Conference on Pituitary Tumors, UCSF
- Oregon Health Sciences University - Endocrine Club
- Philadelphia Endocrine Society, Hahnemann University
- Endocrine Postgraduate Course, Harvard Medical School
- Recent Progress in Hormone Research 51st Conference, Stevenson, Washington
- 5th International Insulin and IGF Symposium, Gainesville, Florida
- International Growth Symposium, Santiago de Compostela, Spain
- Somatostatin Analogs: Basic and Clinical Perspectives, Sorrento, Italy
- Clinical Endocrinology Update; Endocrine Society, San Diego
- 4th International Pituitary Congress, San Diego, CA
- 6th European Workshop on Pituitary Adenomas, Berlin, Germany
- 21st International Symposium: GH & GH factors, Venice, Italy
- 2nd International Skull Base Congress, San Diego
- University of Miami School of Medicine, Visiting Professor, Florida
- South Florida Endocrine Society
- 6th Neuro-immuno-endocrine Networks, NAITO Foundation Nogoya, Japan
- 3rd International Society for Neuro-immunomodulation, Bethesda, MD
- The Biological & Clinical Relevance of the SMS Receptor, Yale, New Haven,
- Mt. Sinai School of Medicine, NY - Visiting Professor
- Paradigm Health Care Acromegaly Teleconference Program
- Neuro-endocrine-Immunology, Gordon Conference - Ventura, CA
- Orange County Endocrine Society, Orange, CA
- The Diagnosis and Treatment of Pituitary Insufficiency, Indianapolis, IN
- Sandostatin LAR Meeting, Innsbruck, Austria
- Endocrine Society 79<sup>th</sup> Ann Mtg, Meet the Professor (Acromegaly), Minneapolis, MN
- 8th European Neuroendocrine Association, Marseille, France

- King Drew Medical Center, CA - Visiting Professor
- Symposium on New aspects of somatostatin analogues, Oslo, Norway
- 3<sup>rd</sup> Scandinavian Symposium on Pituitary Adenomas, Oslo, Norway
- University of California San Diego-Visiting Lecturer, Endocrinology
- Intl Symposium on SMS analogs: Basic update and clinical perspectives, Venice, Italy
- 1998** • Intl Symposium GH: Basic Aspects & New Clinical Applications, Marbella, Spain
- 5<sup>th</sup> International Pituitary Congress, Naples, Florida
- Oregon Health Sciences University, Visiting Lecturer, Endocrinology
- HYPOCCS Symp, Pathogenesis and management of pituitary tumors, Seville, Spain
- Beufour Ipsen Symposium, “Overview of Pituitary tumor management” Seville, Spain
- The 4<sup>th</sup> European Federation of Endo Soc, Seville, Spain
- Endocrine Society Symposium, Growth hormone deficiency in Adults, New Orleans
- Endocrine Society Symposium: “Acromegaly: Pharmacotherapy”, New Orleans
- 5<sup>th</sup> International Pituitary Congress, “Pituitary Oncogenes”, Naples, Florida
- University of Illinois, Chicago, Visiting Professor
- The 2<sup>nd</sup> Parnas Conference, “Cytokine regulation of pituitary function” Gdansk, Poland
- Southern Nevada Endocrine Society, “Indications for growth hormone replacement therapy”
- Society for History of Medicine “Growth hormone from Goliath to receptors”, Los Angeles,
- University of Southern California, “Pathogenesis of Pituitary Tumors”
- Prince Henry’s Trust Visiting Professor, “Pituitary Growth Factors”, Melbourne, Australia
- 1999** • “Criteria for cure of acromegaly: in search of a consensus” Co-Chair, Cortina, Italy
- “Octreotide: the next Decennium”, Sintra, Portugal
- “New pituitary oncogenes” 18<sup>th</sup> Joint Mtg of British Endocrine Society, Bournemouth, UK
- Dopamine resistant prolactinomas” ENEA Mtg. Copenhagen, Denmark
- John Hopkins School of Medicine, Endocrinology Visiting Lecturer
- Annual Meeting Endocrine Society Symposium “Pituitary Oncogenes”
- Controversies in Acromegaly: Point-Counterpoint with leading experts, San Diego
- Chair, GH/IGF-I Workshop, Pasadena
- Simposio Internacional Sobre Patologia Hipofisaria ’99 in Buenos Aires, Argentina
- X International Symposium of Neuroendocrinology, Curitiba, Brazil
- Medical Advances for the Next Century “Recent advances in treatment of pituitary tumors”, Tel Aviv
- 2000** • Clinical Endocrinology Update ’99, (Endocrine Society) Chair, Pituitary Section
- Acromegaly Workshop (Co-Chair), Monte Carlo, France
- Endocrine Society Symposium – “Does acromegaly cause cancer?”, Toronto, Canada
- Chair, 4<sup>th</sup> Annual HypoCCS Symposium and Investigators Meeting Toronto, Canada
- FASEB Plenary Lecture, “Cytokines in the pituitary”, San Diego
- American Association of Neurological Surgeons Annual Meeting, Plenary Lecture, “Recurrent Pituitary Tumors”, San Francisco
- German Endocrine Society “Acromegaly: has time come for primary medical treatment?” and “Pathogenesis of pituitary adenomas” Plenary Lectures, Munich
- 7<sup>th</sup> European Workshop on Pituitary Disease “New pituitary oncogenes”, Oxford, UK
- 11<sup>th</sup> Intl Congress of Endocrinology, “Pathogenesis of pituitary tumors” Sydney, Australia
- Oxford Union Debate: Therapy of acromegaly
- Visiting Professor, Endocrinology, UCSF
- Medical and Subcellular therapy for pituitary tumors, Endo 2000 Satellite Symposium, Toronto (Co-Chair)
- Visiting Professor, Northwestern University School of Medicine

- 2001**
- 43<sup>rd</sup> Spanish Congress of Endocrinology, Santiago de Compostela, Spain, (Plenary)
  - 83<sup>rd</sup> Annual Mtg Endocrine Society, Denver, Colorado  
“Integration of Endocrine Indications for Somatostatin Analogs”
- 2002**
- GH Symposium, “Excess growth hormone and cancer in adults” Tampa, Florida
  - Prolactin Gordon Research Conference, Ventura, California (Vice-Chair)
  - American Federation of Medical Research , “Cytokine receptor-mediated regulation of pituitary function” Carmel, CA (Plenary)
  - Hypoccs Growth Hormone Symposium, “Central & peripheral mechanisms of pituitary disease” Miami, Florida
  - Endo 2002 Symposium, “Novel therapies for pituitary tumors”, San Francisco
  - Acromegaly 2002 and Beyond, “Genetic Syndromes causing Acromegaly”, San Francisco
  - Visiting Lecturer, Brigham and Womens Hospitals, Boston
  - 3<sup>rd</sup> Acromegaly Consensus Conference: Diagnosis & Treatment of acromegaly complications, “Medical treatment options” Versailles, France (Chair)
  - 3<sup>rd</sup> Annual Nicholas T. Zervas Award Lectureship, Harvard Medical School, Massachusetts General Hospital, “Endocrine cell cycle lessons from pituitary adenomas” Boston
  - The Eighteenth Boris Catz, MD Lectureship, “Impact of early thyroid research on clinical medicine”, Cedars-Sinai Medical Center
  - 10<sup>th</sup> Mtg of European Neuroendocrine Association, “Oncogenesis of pituitary tumors” Munich, Germany (Plenary)
  - Endocrine Interventions in aging: Growth Hormone, Univ of South Florida, “GH and cancer”
  - Endocrine Grand Rounds, Univ of California San Diego, “Acromegaly”  
“Guidelines for Acromegaly mangement: a consensus statement, Santa Monica
- 2003**
- 8<sup>th</sup> International Pituitary Congress, “Molecular Pathogenesis of Pituitary Tumors”, NY
  - Global Endocrine Care Summit, “ Mortality of Acromegaly”, Barcelona
  - Endocrine Board Review Course, University of California San Diego
  - Chair, 4<sup>th</sup> Consensus Workshop on Acromegaly “Issues in Medical Treatment”, Spain
  - Chair, Pituitary Young Investigators Meeting, Nevada
- 2004**
- 77<sup>th</sup> Annual Meeting of Japan Endocrine Society (Plenary), International satellite symposium, Kyoto Japan “Zebrafish pituitary development and regulation”, “Molecular pathogenesis of pituitary”, “Diagnosis of GH deficiency in adults?”
  - Honorary Professor and Chair, Acromegaly consensus guidelines for Asia Pacific and Latin America, Fudan University, Shanghai “Goals of clinical management for acromegaly”
  - Chair, Prolactin Gordon Conference, Oxnard, CA
  - Program Chair, International Congress of Endocrinology, Lisbon, Portugal
  - Satellite Symposium, 12<sup>th</sup> ICE “Acromegaly: new development in therapy”
  - Visiting Professor, New York University, New York
  - Endocrine Society Clinical Investigator Award Lecture, New Orleans, Louisiana  
Endocrine Fellows Foundation “Basic aspects of pituitary function”
  - European Neuroendocrine Association, Naples, Italy
  - Societa Italiana Di Endocrinologia, Sie Lombardia Lecture 2004 “Oncogenesis: the lesson from pituitary tumors”
  - Argentine Endocrine Society, Buenos Aires – Plenary lectures: “Advances in hypophyseal tumorogenesis” and “Controversies in the treatment of acromegaly”
  - 26<sup>th</sup> Endocrinology and Metabolism Brazilian Congress, “Acromegaly-clinical treatment: where are we?”
  - Acromegaly Patient Education Symposium –NY, New York.
- 2005**
- HYPOCCS Molecular Pathogenesis and Therapy of Pituitary Disease Madrid, Spain
  - University of California San Diego - Endocrine Grand Rnds

- Robert L. Ney Visiting Professor, Johns Hopkins University, MD
- 5<sup>th</sup> Colloques Medecine et Recherche, “Insights into receptor function and new drug development targets”, Paris, France
- Pituitary Today: Molecular, physiological and clinical aspects”, Argentina-Brazil,Iguazu
- International Workshop “Somatostatin update”, Turin, Italy Sept 16-17.
- California Chapter of AACE, 5<sup>th</sup> Annual Mtg “Update on Management of Acromegaly.

## 2006

- V Consensus Meeting on “Guidelines for treatment of GH excess and GH deficiency in the adult”, Santa Monica
- Yogesh Patel Memorial Lecture Annual Endocrine Retreat at McGill University, “Pituitary Tumor Pathogenesis”
- Visiting Professor, Dean’s Lecture: “How to succeed in Academic Medicine- Is it worth it?” University of South Florida, Tampa, Oct 5-8.
- 4<sup>th</sup> National Symposium on Pituitary Disorders: “Evaluation of pituitary mass treatment of acromegaly”, USF, Tampa.
- “Pituitary trophic status as a tumorigenic determinant”, Hormonal Control of Cell Cycle Paris, France, Ipsen Foundation, Dec 4.

## 2007

- Growth and Signaling: Pathogenesis of pituitary tumors, Inserm, Paris, France, Dec.
- Endocrinology Grand Rounds and Clinical Case Conference, “Update on Acromegaly Management” UCSF, San Francisco, CA. Feb 21.
- UCSD Endocrinology Grand Rounds and Lecture, “Mechanisms for pituitary tumor Pathogenesis” and “Treatment of Acromegaly”, March.

## 2008

- International Workshop on Treatment of Cushing’s Syndrome, Budapest, Hungary, April
- The Endocrine Society 89<sup>th</sup> Meeting, “The Year in Pituitary” Toronto, Canada, June.
- Prolactin and Growth Hormone Gordon Conference, Ventura, Pituitary Tumor Pathogenesis, Pituitary Expert Symposium, Pituitary Senescence, Florence, Italy
- The Endocrine Society 90<sup>th</sup> Meeting, Clinical Investigators Talk: “Conversations about pituitary disorders and pituitary tumors, San Francisco, CA.

## 2009

- Grand Rounds “Acromegaly” University of Tucson, Tucson, AZ, July.
- Pituitary Today II: Molecular, Physiological and Clinical Aspects. Brazil, November.
- Western Society for Clinical Investigation. Endocrine Plenary: “Pituitary Tumor Pathogenesis”, Carmel, January.
- Chair, Acromegaly Consensus Criteria for Cure: Cortina revisited after 10 years”, Paris, April.
- Bridges in Life Sciences US-CEE Regional networking Mtg IV, “Molecular Mechanisms for Pituitary Tumorigenesis:” Debrecen, Hungary, April.
- Co-Chair, International Pituitary Congress, Washington, DC, June.
- Course Director, PeerView Institute for Medical Education, CME activity, “Improving outcomes in Acromegaly and Cushing’s Disease”, Los Angeles, July.
- Dinner symposium, Book “Acromegaly”: 2<sup>nd</sup> Edition Launch, “The Senescent Pituitary”, Washington, DC, July

## 2010

- British Society of Endocrinology: Transatlantic Lecture, “Pituitary Tumor Pathogenesis” and Meet the Expert “Acromegaly”, Manchester, UK, March
- Pfizer Visiting Professor, Mount Sinai Medical Center, New York, May
- Endocrine Society Trainee Day, Plenary “Discovery in Pituitary Medicine”, San Diego, June
- Endocrine Society Symposium, “Targeted therapy for pituitary tumors”, San Diego, June
- Congress of European Neuroendocrine Association (Enea) - Fondation Ipsen Endocrine Regulation Prize Award in Liege, Belgium

## 2011

- American Association of Clinical Endocrinologists (AACE) 2011 Annual Meeting – “Medical therapy for acromegaly”, San Diego, April

- European Congress of Endocrinology (Invited) – “Approaches to acromegaly treatment resistance”, Rotterdam, Netherlands, May
- 2<sup>nd</sup> Annual Pan-European Meeting Management of Acromegaly, Athens, Greece – September
- Targeting the Pituitary: Expert Knowledge Forum, “The science of acromegaly: molecular and genetic insights” Berlin, Germany – November
- 2012**
  - “Clinical and Economic Impact of Acromegaly”, Regional Cooperation for Health, Science and Technology Consortium, Budapest, Hungary- March
  - “Focus on pituitary tumors: progress in medical management for acromegaly and cushing’s disease”, Medicine Grand Rounds, City of Hope, Duarte- May
  - Emory University, Medicine Grand Rounds, “Focus on Pituitary Tumors: Progress in Medical Management for Acromegaly and Cushing Disease”, Atlanta, GA- May
  - Emory University, Endocrine Research Conference, ““New targets for pituitary tumor therapy””, Atlanta, GA- May
  - American Association of Clinical Endocrinology “Medical Management for Acromegaly and Cushing Disease”, Atlanta, GA-May
  - 15<sup>th</sup> International Congress of Endocrinology/14<sup>th</sup> European Congress of Endocrinology – “Genes involved in pituitary tumorigenesis” Florence, Italy- May
  - 15<sup>th</sup> International Congress of Endocrinology/14<sup>th</sup> European Congress of Endocrinology- “Economic value of disease control”, Florence, Italy- May
  - Italian Endo Society “Pathogenesis of Pituitary Adenomas”, Brescia, Italy- September
  - Chair, Updates in Diagnosis and Treatment of Cushing’s Disease: A Pituitary Society Workshop, “Treatment Algorithms” - Toronto, Canada, September, 2012
- 2013**
  - Co-Chair, 9th Acromegaly Consensus Conference: “Medical Treatment of Acromegaly”, Amsterdam, The Netherlands, March (Co-Chair)
  - 15<sup>th</sup> European Congress of Endocrinology, Copenhagen, Denmark, April (Symposium Chair)
  - The Endocrine Society’s Visiting Professorship in Growth Hormone Regulation and Disorders, University of Colorado: May
  - 13<sup>th</sup> International Pituitary Congress, San Francisco, CA June (Co-Chair)
  - Latin American Knowledge Network Cedars-Sinai Med Ctr, Lecture “New insights into pituitary tumor therapies”, October
  - Aspiring to Excellence: Pituitary Expert Forum, Stockholm, Sweden, October.
  - 60 minutes Interview “Deer Antler” with Keith Sharman, CSMC, October
  - Memorial Sloan-Kettering Center, NY “Pituitary Tumor Therapeutic Targets”, November.
  - CSMC Annual Meeting “Turning Discovery into Health”, Beverly Hills, CA, December
  - 6th Joint SPED-AACE (Puerto Rican Society of Endocrinology and Diabetes), Puerto Rico, December.
- 2014**
  - International Symposium of Neuroendocrinology (SINE), “Acromegaly: Past, present and future management”, Campinas, Brazil, April
  - AACE 23<sup>rd</sup> Annual meeting Chair: Acromegaly: Assessing the Disorder and Therapeutic Options, Las Vegas, NV, May.
  - ICE/Endo CMES Ancillary Symposium of Acromegaly: Diagnosis and Management Options,” Chicago, IL, June
  - 16<sup>th</sup> Congress of European Neuroendocrine Association (ENA) Meeting: “Why are pituitary tumors benign?” Sofia, Bulgaria, September.
- 2015**
  - John Wayne Cancer Institute, Pituitary Centers of Excellence “What Do We Expect From Our Neurosurgical Colleagues”, Santa Monica, CA
  - Department of Medicine Grand Rounds, UC Irvine Medical Center “*Pituitary tumor signaling pathways as therapeutic targets*”, Irvine, February.
  - 14<sup>th</sup> International Pituitary Congress, Co-Chair, San Diego, CA, March.
  - 10<sup>th</sup> Acromegaly Consensus Conference, Co-Chair, Madrid, Spain, April.

- Endocrine Society Clinical Endocrinology Update, “Update in Management of Pituitary Adenomas – Year in Clinical Pituitary” and “Pituitary/Adrenal Imaging” Miami, September.
  - 5<sup>th</sup> Pituitary Standalone Meeting: Aspiring excellence: Pituitary Expert Forum, Barcelona, “Molecular targets for treatment of pituitary tumors” Spain, October.
  - UCSF, Pituitary Disorders: Advances in Diagnosis and Management “Pituitary signaling pathways leading to novel therapies”; “Non-surgical approaches for large pituitary masses”; “Acromegaly management update”, San Francisco, October.
  - Partnering Forum - Stem Cell Meeting on the Mesa for Alliance for Regenerative Medicine. Payer Access Panel – ARM Advanced Therapies, La Jolla, CA, October.
- 2016**
- Global Pituitary Expert Round Table, Zurich, Switzerland, February
  - AACE Annual Meeting “Does GH keep you younger?”, Orlando, FL, May
  - Combined Neurosurgery & Pituitary Conference, Las Vegas, NV, October

### PATENTS ISSUED

1. **Melmed/Akita/Readhead** – Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs. *United States Patent No. 5,824,838, 1998.*
2. **Melmed/Shimon/Culler** – Method of treating hyperprolactinemia and prolactinomas, *United States Patent No. 5,972,893, 1999.*
3. **Melmed/Pei** – Pituitary tumor transforming genes, and related products. *United States Patent No. 6,455,305, 2002.*
4. **Auernhammer/Melmed** – Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans. *United States Patent No. 6,541,244, 2003*
5. **Melmed/Pei** – Compositions a method for determining the presence of human PTTG peptide in a sample. *US Patent No. 6,750,327, 2004*
6. **Horwitz/Zhang/Melmed** - Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation. *US Patent no. 6,858,586, 2005*
7. **Melmed/Pei** – Human PTTG polypeptide and method for producing it. *US Patent no. 6,900,032, 2005*
8. **Melmed/Pei** – Rat PTTG polypeptide and method for producing it. *US Patent no. 6,911,320, 2005*
9. **Horwitz/Zhang/Melmed** – PTTG Carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation), *US Patent no. 6,894,031, 2005.*
10. **Melmed/Wang** - PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes. *US Patent no. 6,909,030, 2005.*
11. **Prezant/Heaney/Melmed** – Method of regulating biological activity of pituitary tumor transforming gene (PTTG) 1 using PTTG2. *US Patent no. 6,913,926, 2005.*
12. **Auernhammer/Melmed** – Transgenic expression from a SOCS-3 promoter in vertebrate cells. *US Patent no. 6,943,018, 2005.*
13. **Horwitz/Zhang/Melmed** – Antibodies against rat pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides. *US Patent no. 6,835,380, 2004.*
14. **Heaney/Melmed** – Use of peroxisome proliferator activated receptor (PPAR)-gamma ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome. *US Patent no. 6,673,823, 2004.*
15. **Heaney/Melmed** - Transgenic cells transfected with pituitary tumor transforming gene (PTTG) expression vectors and uses therefore. *US Patent no. 7,097,829, 2006.*

16. **Ben-Shlomo/Melmed/Wawrowsky** – Methods for drug screening and characterization by ion flux analysis. *Patent Pending – International Application Number PCT/US2005/046468 (Published in 2006)*
17. **Melmed/IsHak/Berman** – Treatment of anorgasmia or delayed orgasm. *US Patent Pending Application no. 11/324,983, 2006.*
18. **Melmed/Fukuoka** – Use of tyrosine kinase inhibitors for treatment of cushing's disease and hypercortisolism". *US Patent pending application no. 61/300,379, 2010, Intl Patent application no. PCT/US11/23247, 2011(Published).*
19. **Tong/Melmed** – PTTG1 as a biomarker for cancer treatment. *US Patent no. 8,216,782 Granted 2012.*
20. **Fukuoka/Cooper/Melmed**- *Use of tyrosine kinase inhibitors for treatment of prolactinoma. US Patient No 094716, 2011 (Published).*
21. **Melmed/Liu** – *Treatment of pituitary corticotroph tumors using R-roscovitine. US Patent No 061601, 2012 (Published).*

## BIBLIOGRAPHY

### PEER-REVIEWED PUBLICATIONS:

1. Lewin L, **MELMED S**, Bank H: Rapid screening test for detection of elevated myo-inositol levels in human serum. Clin Chimica Acta 54:377, 1974.
2. **MELMED S**, Bank H, Lewin L: Clinical significance of increased serum myo-inositol levels. Israel J Med Sci 10:1518, 1974.
3. **MELMED S**, Bank H: Metoclopramide and facial dyskinesias. Brit Med J 1:331, 1975.
4. **MELMED S**, Bank H: Meningitis complicated by eighth nerve deafness and arthritis. Harefuah 79:22, 1975.
5. **MELMED S**, Lewin L, Bank H: Myo-inositol-metabolic and clinical aspects. Harefuah 79:472, 1975.
6. **MELMED S**, Bank H, Katz D: Streptococcal pancarditis. Chest 69:108, 1976.
7. **MELMED S**, Lewin L, Bank H: Serum myo-inositol concentration in impaired renal function. Proc 13th Int Congress Int Med Helsinki p 139, 1976.
8. Bank H, **MELMED S**, Gross S: Azathioprine in the management of subacute thyroiditis. Proc 13th Int Congress Int Med Helsinki p. 85, 1976.
9. **MELMED S**, Lewin L, Bank H: Myo-inositol clearance in renal failure and in patients with normal kidney function. Am J Med Sci 274:55, 1977.
10. **MELMED S**, Martinovitz U, Bank H: Menigo-myelitis associated with mycoplasma pneumoniae pneumonia. Harefuah 82:353, 1977.
11. Agranat O, **MELMED S**, Altman G, Bank H: Bacterial and fungal meningitis: 22 year survey in a large general hospital. Israel J Med Sci 13:1151, 1977.
12. Lewin L, **MELMED S**, Passwell J, Brish M, Boichis H, Bank H: Myo-inositol in human neonates: Serum concentrations and renal handling. Pediatric Research 12:3, 1978.
13. Sharon P, **MELMED S**, Neuman G: Acute pancreatitis in a community with a low alcohol intake. Int Surg 64:64, 1979.
14. **MELMED S**, Kurtzman G, Reed A, Hershman JM: Non-thyrotropic pituitary cells in culture convert T4 to T3. Life Sci 24:1947, 1979.
15. **MELMED S**, Harada A, Murata Y, Reed A, Carlson H, Azukizawa M, Martin C, Jorgensen E, Hershman JM: Fetal responses to TRH after thyroid hormone administration to the rhesus monkey: Lack of pituitary suppression. Endocrinology 105:334, 1979.
16. Morley JE, Barnetsky N, Wingert T, Carlson HE, Hershman JM, **MELMED S**, Levin SR, Weitzman R, Chang RJ, Varner AA: Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 50:251, 1980.



17. Morley JE, **MELMED S**, Reed A, Kasson BG, Levin RS, Pekary AE, Hershman M: Effect of vitamin A on the hypothalamic-pituitary-thyroid axis. *Am J Physiol* 238:E174, 1980.
18. **MELMED S**, Harada A, Hershman JM, Krishnamurthy T, Bland W: Development of neutralizing antibodies in immunized patients with thyroid carcinoma. *J Clin Endocrinol Metab* 51:358, 1980.
19. **MELMED S**, Spira O, Gordon A, Gross J, Hershman JM: Suppression of TSH by 3, 5, dimethyl-3'-isopropyl-L-thyronine in euthyroid and hypothyroid rats. *Endocrinology* 107:1050, 1980.
20. **MELMED S**, Carlson HE, Murata Y, Socol M, Hershman JM: Fetal and maternal growth hormone levels in the rhesus monkey: Responses to TRH. *Neuroendocrinol Lett* 1:89, 1979.
21. **MELMED S**, Carlson HE, Briggs J, Hershman JM: Cell culture alters the hormonal responses of rat pituitary tumors to dynamic stimulations. *Endocrinology* 107:789, 1980.
22. **MELMED S**, Carlson HE, Briggs JE, Hershman JM: Autofeedback of prolactin in cultured pituitary cells. *Horm Res* 12:340, 1980.
23. **MELMED S**, Nelson M, Kaplowitz N, Yamada T, Hershman JM: Role of intracellular glutathione in modulation of thyroxine conversion to triiodothyronine and hormone production by cultured pituitary cells. In: Thyroid Research, Stockigt JR, Nagataki S (Eds), *Australian Academy of Science*, Canberra, p 453, 1980.
24. Sack J, Sazbon L, **MELMED S**, Lunenfeld B, Najenson T: Low serum triiodothyronine and reverse triiodothyronine concentrations in patients with prolonged coma. *Israel J Med Sci.* 16:402, 1980.
25. **MELMED S**, Nelson M, Kaplowitz N, Yamada T, Hershman JM: Glutathione-dependent thyroxine 5'-monodeiodination modulates growth hormone production by cultured non-thyrotropic rat pituitary cells. *Endocrinology*, 108:970-976, 1981.
26. Sharp B, Morley JE, Carlson HE, **MELMED S**, Hershman JM: Role of endogenous opiate peptides in the regulation of rat TSH secretion. *Brain Research* 219:335-344, 1981.
27. **MELMED S**, Park J, Hershman JM: Triiodothyronine induces a transferable factor which suppresses TSH secretion in cultured mouse thyrotropic tumor cells. *Biochem Biophys Res Comm* 98:1022-1028, 1981.
28. Sharp B, **MELMED S**, Goldberg R, Carlson HE, Refetoff S, Hershman JM: Radioimmunoassay detection of endorphin from longterm culture of human pituitary tumor cells. *Acta Endocrinol* 99:174-178, 1982.
29. **MELMED S**, Odenheimer D, Carlson HE, Hershman JM: Establishment of functional human pituitary tumor cell cultures. *In Vitro* 18:35-42, 1982.
30. **MELMED S**, Nademanee K, Reed AW, Hendrickson J, Singh BN, Hershman JM: Hyperthyroxinemia with bradycardia and normal thyrotropin secretion following chronic amiodarone administration. *J Clin Endocrinol Metab* 53:997-1001, 1981.
31. **MELMED S**, Carlson HE, Hershman JM: Histidyl-proline diketopiperazine suppresses prolactin secretion in human pituitary tumor cell cultures. *Clin Endocrinol* 16:97-100, 1982.
32. Lewin LM, Yannai Y, **MELMED S**, Weiss M: Myo-inositol in the reproductive tract of the female rat. *Int J Biochem* 14:147-150, 1982.
33. **MELMED S**, Geola F, Reed AW, Pekary AE, Park J, Hershman JM: Comparison of methods for assessing thyroid function in non-thyroid illness. *J Clin Endocrinol Metab* 54:300-306, 1982.
34. Socol ML, Druzin ML, Murata Y, **MELMED S**, Martin C Jr., Hershman JM: A cyclic variation in thyroid-stimulating hormone in the fetal rhesus monkey. *Am J Obstet Gynecol* 139:712-714, 1981.
35. Nademanee K, Singh BN, Hendrickson JA, Reed AW, **MELMED S**, Hershman JM: Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: A potential method for monitoring chronic drug therapy. *Circulation* 66:202-211, 1982.
36. Neufeld N, **MELMED S**: 3,5,-dimethyl-3'-isopropyl-L-thyronine therapy in diabetic pregnancy: Stimulation of fetal lung phospholipids. *J Clin Invest* 68:1605-1609, 1981.
37. **MELMED S**: Bromocriptine inhibits colony formation by rat pituitary tumor cells in a double-layered agar colonogenic assay. *Endocrinology* 109:2258-2260, 1981.

38. **MELMED S**, Braunstein GD, Hershman JM, Wade MC: Modulation of ectopic secretion of human chorionic gonadotropin by cultured ovarian adenocarcinoma cells. Gynecol Oncol 16:49-55, 1983.
39. **MELMED S**: GH3 rat pituitary tumor cells are deficient in hypoxanthine-guanine phosphoribosyl transferase activity. Biochem Biophys Res Commun 108:1460-1466, 1982.
40. **MELMED S**, Braunstein GD: Human chorionic gonadotropin stimulates proliferation of Nb 2 rat lymphoma cells. J Clin Endocrinol Metab 56:1068-1070, 1983.
41. **MELMED S**: Isolation of human x mouse somatic cell hybrids producing human prolactin: Dominant expression of hormone secretion and regulation. J Clin Endocrinol Metab 56:1145-1151, 1983.
42. Cheung CY, **MELMED S**, Braunstein GD: Dopaminergic regulation of prolactin and growth hormone synthesis in rat pituitary tumor cells. Brain Research 270:165-168, 1983.
43. Davidson MB, **MELMED S**: Hepatocyte insulin binding and action in rats with sommatomammotrophic tumors. Diabetologia 25:60-65, 1983.
44. **MELMED S**: Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest 73:1425-1433, 1984.
45. Davidson MB, **MELMED S**: Insulin binding and action in rats bearing growth hormone secreting transplantable tumors. In: Lessons from Animal Diabetes, Ed. by Shafrir E, Renold AE, p 231, London: John Libbey, 1984.
46. Gilbert PL, Siegel RJ, **MELMED S**, Sherman CT, Fishbein MC: Cardiac morphology in rats with growth hormone-producing tumors. J Mol Cell Cardiol 17:805-811, 1985.
47. **MELMED S**, Ezrin C, Kovacs K, Goodman R, Frohman LA: Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet cell tumor. New Engl J Med 312:9-17, 1985.
48. **MELMED S**, Neilson L, Slanina S: Insulin suppresses rat growth hormone messenger RNA levels in rat pituitary tumor cells. Diabetes 34:409-412, 1985.
49. **MELMED S**, Slanina SM: Insulin suppresses triiodothyronine-induced growth hormone secretion by GH3 rat pituitary cells. Endocrinology 117:532-537, 1985.
50. Drazzin B, Mehler PS, Leitner JW, Sussman KE, Dahl R, Vatter A, **MELMED S**: Localization of somatostatin receptors in secretion vesicles in anterior pituitary cells and pancreatic islets. J Recept Res 5:83-103, 1985.
51. **MELMED S**, Fagin J, Leung M: Bromocriptine inhibits incorporation of 3H-thymidine into rat pituitary tumor cells. Brain Research 369:83-90, 1986.
52. Yamashita S, **MELMED S**: Insulin-like growth factor I action on rat anterior pituitary cells: Suppression of growth hormone secretion and messenger RNA levels. Endocrinology 118:176-182, 1986.
53. **MELMED S**, Fagin J: Isolation and characterization of rat-mouse somatostatin cell hybrids secreting growth hormone and prolactin. Exptl Cell Res 162:475-485, 1986.
54. Yamashita S, **MELMED S**: Suppression of triiodothyronine-induced growth hormone messenger RNA by insulin-like growth factor-I in thyroidectomized rat pituitary cells. Frontiers in Thyroidology 1:697-700, 1986.
55. Yamashita S, **MELMED S**: Effects of insulin on rat anterior pituitary cells: Inhibition of growth hormone secretion and mRNA levels. Diabetes 35:440-447, 1986.
56. Yamashita S, Slanina S, Kado H, **MELMED S**: Autoregulation of pituitary growth hormone mRNA levels in rats bearing transplantable mammosomatotropic pituitary tumors. Endocrinology 118:915-918, 1986.
57. **MELMED S**, Yamashita S: Insulin-like growth Factor-I action on hypothyroid rat pituitary cells: Suppression of triiodothyronine-induced growth hormone secretion and messenger RNA levels. Endocrinology 118:1483-1490, 1986.
58. Neufeld ND, Braunstein GD, **MELMED S**, Corbo L, Razor J: Prenatal Therapy in Experimental Diabetic Pregnancy: Association with Fetal Lung Maturity. J Perinatol 6:101, 1986.
59. Karpf D, Yamashita S, **MELMED S**, Kudish H, Braunstein GD: In vitro secretion of deoxycorticosterone by a benign Leydig cell tumor of the testis. J Urol 136:114, 1986.

60. Yamashita S, Weiss M, **MELMED S**: Insulin-like growth-factor I regulates growth hormone secretion and messenger RNA levels in human pituitary tumor cells. *J Clin Endocrinol Metab* 63:730-735, 1986.
61. Yamashita S, Ong J, Fagin JA, **MELMED S**: Expression of the myc cellular oncogene in human thyroid tissues. *J Clin Endocrinol Metab* 63:1170-1173, 1986.
62. Yamashita S, **MELMED S**: Insulin regulation of rat growth hormone gene transcription. *J Clin Invest* 78:1008-1014, 1986.
63. Ong J, Yamashita S, **MELMED S**: Insulin-like growth factor I induces c-fos messenger RNA in L6 rat skeletal muscle cells. *Endocrinology* 120:353-357, 1987.
64. Fagin JA, **MELMED S**: Relative increase in insulin-like growth factor I messenger RNA levels in compensatory renal hypertrophy. *Endocrinology* 20:718-724, 1987.
65. Yamashita S, **MELMED S**: Insulin-like factor-I regulation of growth hormone gene transcription in primary rat pituitary cells. *J Clin Invest* 79:449-452, 1987.
66. **MELMED S**, Yamashita S, Kovacs K, Ong J, Rosenblatt S, Braunstein GD: Cushing's syndrome due to ectopic proopiomelanocortin gene expression by islet cell carcinoma of the pancreas. *Cancer* 59:(4)772-778, 1987.
67. Alexander N, **MELMED S**, Morris M: Suppressed serum prolactin levels in sino-aortic denervated rats. *Am J Physiol* 21:R290-293, 1987.
68. Fagin JA, Pixley S, Slanina S, Ong J, **MELMED S**: IGF-I gene expression in GH3 rat pituitary cells. *Endocrinology* 120:2037-2043, 1987
69. Pixley S, Weiss M, **MELMED S**: Identification of human growth hormone messenger ribonucleic acid in pituitary adenoma cells by in situ hybridization. *J Clin Endocrinol Metab* 65:575-580, 1987.
70. Yamashita S, Ong J, **MELMED S**: Regulation of human growth hormone gene expression by insulin-like growth factor I in transfected cells. *J Biol Chem* 262:13254-13257, 1987.
71. Morita S, Yamashita S, **MELMED S**: IGF-I action on rat anteriorpituitary cells: Effects of intracellular messengers on growth hormone secretion and messenger RNA levels. *Endocrinology* 121:2000-2006, 1987.
72. Fagin S, Brown A, **MELMED S**: Regulation of pituitary IGF-I mRNA levels in rats harboring somatomammotropic tumors: implications for growth hormone autoregulation. *Endocrinology* 122:2204-2210, 1988.
73. Prager D, Yamashita S, **MELMED S**: Insulin regulates prolactin secretion and messenger RNA levels in pituitary cells. *Endocrinology* 122:2946-2952, 1988.
74. **MELMED S**, Ziel F, Braunstein GD, Downs T, Frohman LA: Medical management of ectopic production of growth hormone releasing hormone by a carcinoid tumor. *J Clin Endo Metab* 67 (2):395-399, 1988.
75. Prager D, **MELMED S**: Insulin regulates expression of the human growth hormone gene in transfected cells. *J Biol Chem* 263:16580-16585, 1988.
76. Mc Allister T, Price T, **MELMED S**: Lack of effect of naloxone on prolactin and seizures in electroconvulsive therapy. *Epilepsia* 30 (1):41-44, 1989.
77. Namba S, Morita S, **MELMED S**: Insulin-like growth factor I action on growth hormone secretion and mRNA levels: interaction with somatostatin. *Endocrinology* 124:1794-1799, 1989.
78. Barakat S, **MELMED S**: Reversible shrinkage of a growth hormone secreting pituitary adenoma by a long-acting somatostatin analog, SMS 201-995. *Archives of Int Med* 149:1443-1445, 1989.
79. Morita S, Fernandez C, **MELMED S**: Retinoic acid selectively stimulates growth hormone secretion and messenger ribonucleic acid levels in rat pituitary cells. *Endocrinology* 124:2052-2056, 1989.
80. Fagin JA, Fernandez-Mejia C, **MELMED S**: Pituitary Insulin-like growth factor I gene expression: Regulation by triiodothyronine and growth hormone. *Endocrinology* 125:2385-2391, 1989.
81. Siegel RJ, Fishbein MC, Said JW, Fealy M, Chai A, Rubin SA, **MELMED S**: Identification of growth hormone at the myocardial cell surface. *Am J Cardiovascular Path* 2:345-350, 1989.
82. Prager D, Gebremedhin S, **MELMED S**: An insulin-induced DNA-binding protein for the human growth hormone gene. *J Clin Invest*, 85:1680-1685, 1990.

83. Matsuo K, Yamashita S, Niwa M, Kurihara M, Harakawa S, Izumi M, Nagataki S, **MELMED S**: Thyroid hormone regulates rat pituitary insulin-like growth factor-I receptors. Endocrinology 126:550-554, 1990.
84. Rubin SA, Buttrick P, Malhotra A, **MELMED S**, Fishbein MC: Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Mol and Cell Cardiology 22:429-438, 1990.
85. Harakawa S, Yamashita S, Tobinaga T, Matsuo K, Hirayu H, Izumi M, Nagataki S, **MELMED S**: In vivo regulation of hepatic insulin-like growth factor-I messenger ribonucleic acids with thyroid hormone. Endocrinology Japan 37:205-211, 1990.
86. Herman V, Fagin J, Gonsky R, Kovacs K, **MELMED S**: Clonal origin of pituitary adenomas. J Clin Endocrinol and Metab 71:1427-1433, 1990.
87. Herman V, Weiss M, Becker D, **MELMED S**: Hypothalamic hormonal regulation of human growth hormone gene expression in somatotroph adenoma cell culture. Endocrine Pathology 1:236-244, 1990.
88. Yamasaki H, Prager D, Gebremedhin S, Moise L, **MELMED S**: Binding and action of insulin-like growth factor I in pituitary tumor cells. Endocrinology 128:857-862, 1991.
89. Shohat M, Herman V, **MELMED S**, Neufeld N, Shrech R, Pulst S, Graham JM, Rimoin DL, Korenberg JR: Deletion of 20p 11.23 ->pter with growth hormone neurosecretory disorder but normal growth hormone releasing hormone gene. Am J Human Genetics 39:56-63, 1991.
90. Ezzat S, Laks D, Oster J, **MELMED S**: Growth hormone regulation in primary fetal and neonatal rat pituitary cell cultures: The role of thyroid hormone. Endocrinology 128:937-943, 1991.
91. Ezzat S, Strom C, **MELMED S**: Colon polyps in acromegaly. Annals Internal Medicine 114:754-755, 1991.
92. Yamasaki H, Prager D, Gebremedhin S, **MELMED S**: Insulin-like growth factor I attenuation of growth hormone is enhance by over-expression of pituitary insulin-like growth factor I receptors. Molecular Endocrinology 5:890-896, 1991.
93. Ezzat S, Ren SG, Braunstein GD, **MELMED S**: Octreotide stimulates insulin-like growth factor binding protein 1 levels in acromegaly. J Clin Endo Metab 73:441-443, 1991.
94. Gonsky R, Herman VS, **MELMED S**, Fagin J: Transforming DNA sequences isolated from human prolactin-secreting pituitary tumors. Molecular Endocrinology 5:1687-1695, 1991.
95. Ren SG, Ezzat S, **MELMED S**, Braunstein GD: Somastatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 131:2479-2481, 1992.
96. Weber MM, **MELMED S**, Rosenbloom J, Yamasaki H, Prager D: Rat somatotroph insulin-like growth factor II signalling: Role of the insulin-like growth factor I receptor. Endocrinology 131:2147-2153, 1992.
97. Yamasaki H, Prager D, Gebremedhin S, **MELMED S**: Human IGF-I receptor 950Tyrosine is required for somatotroph growth factor signal transduction. J Biol Chem 267:20953-20958, 1992.
98. Ezzat S, Ren SG, Braunstein GD, **MELMED S**: Octreotide stimulates IGF binding protein 1: A potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 75:1459-1463, 1992.
99. Prager D, Yamasaki H, Weber M, Gebremedhin S, **MELMED S**: Human IGF-I receptor function in pituitary growth hormone-secreting cells is suppressed by a dominant negative mutant. J Clin Invest 90:2117-2122, 1992.
100. Ezzat S, Snyder PJ, Young WF, Boyajy, LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, **MELMED S**: Octreotide treatment of acromegaly a randomized, multicenter study. Ann Int Med 117:711-718, 1992.
101. Ezzat S, **MELMED S**: Endocrine applications of the somatostatin analogue octreotide (Sandostatin). Metab Clin and Exp 41:34-38, 1992.
102. Ezzat S, Ezrin C, Yamashita S, **MELMED S**: Recurrent acromegaly due to ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer 71:66-70, 1993.

103. Prager D, Weber MM, Gebremedhin S, **MELMED S**: Interaction between insulin and thyroid hormone in rat pituitary tumor cells: insulin attenuates T3-induced growth hormone mRNA levels. J of Endocrinology 137:107-114, 1993.
104. Smith RA, **MELMED S**, Sherman B, Frane J, Munsat TL, Festoff BW: Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle and Nerve 16:624-633, 1993.
105. **MELMED S**: Medical management of acromegaly - what and when? Acta Endocrinol, 1993.
106. Ezzat S, **MELMED S**, Endres D, Eyre DR, Singer FR: Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 76:1452-1457, 1993.
107. Yamasaki H, Prager D, **MELMED S**: Structure-function of the human IGF-I receptor: A discordance of somatotroph internalization and signaling. Molecular Endocrinol 7:681-685, 1993.
108. Herman V, Drazin N, Gonsky R, **MELMED S**: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77:50-55, 1993.
109. Yamamoto H, Prager D, Yamasaki H, **MELMED S**: Rat pituitary GC cell insulin-like growth factor I receptor regulation. Endocrinology 133:1420-1425, 1993.
110. Prager D, Yamasaki H, Li J, **MELMED S**: Human insulin-like growth factor I receptor internalization role of the juxtamembrane domain. J Biol Chem 269:11934-11937, 1994.
111. **MELMED S**, Dowling RH, Frohman L, Ho K, Lamberts SWJ, LaMont JT, Sassolas G, Schoenfield L, Snyder P, Wass JAH: Consensus statement: benefits vs. risks of medical therapy for acromegaly. Am J of Med 97:468-473, 1994.
112. Greenman Y, **MELMED S**: Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403, 1994.
113. Pei L, **MELMED S**, Scheithauer B, Kovacs K, Prager D: H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 78:842-846, 1994.
114. Prager D, Hsiao-Lin, Asa S, **MELMED S**: Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci 91:2181-2185, 1994.
115. Prager D, Yamasaki H, Weber MM, **MELMED S**: Role of the insulin-like growth factors in regulating neuroendocrine function. Neurobiology of Aging 15:569-572, 1994.
116. Greenman Y, **MELMED S**: Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729, 1994.
117. Webster J, Prager D, **MELMED S**: Insulin-like growth factor-I activation of extracellular signal-related kinase-1 and -2 in growth hormone-secreting cells. Mol Endocrinol 8:539-544, 1994.
118. Pei L, **MELMED S**: The neurofibromatosis gene in human pituitary adenomas. Endocrine Pathol 5:229-232, 1994.
119. Greenman Y, Prager D, **MELMED S**: IGF-I receptor sub-membrane is intact in GH-secreting pituitary tumors. Clin Endo 42:169-172, 1994
120. Akita S, Webster J, Ren S-G, Takino H, Said J, Zand O, **MELMED S**: Human and murine pituitary expression of leukemia inhibitory factor (LIF) novel intrapituitary regulation of adrenocorticotropin hormone (ACTH) synthesis and secretion. J Clin Invest 95:1288-1298, 1995.
121. Pei L, **MELMED S**, Scheithauer B, Benedict WF, Kovacs K, Prager D: Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB<sup>1</sup>. Cancer Research 55:1613-1616, 1995.
122. Takino H, Herman V, Weiss M, **MELMED S**: Purine-binding factor (NM23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80:1733-1738, 1995.
123. Newman CB, **MELMED S**, Snyder PJ, Young WF, Boyaji LD, Stewart WN, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Van ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, Kleinberg DL: Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients. J Clin Endocrinol Metab 80:2768-2775, 1995.
124. Pei L, **MELMED S**: Characterization of the rat vasoactive intestinal polypeptide (VIP) receptor 5' region. Biochem Journal 308:719-723, 1995.

125. Rosenfeld RG, Albersson-Wikland K, Cassorla F, Douglas Frasier S, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, **MELMED S**, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA: Diagnostic Controversy: The diagnosis of childhood growth hormone deficiency revisited. *J Clin Endocrinol Metab* 80:1532-1540, 1995.
126. Greenman Y, Woolf P, Coniglio J, Mara RO, Pei L, Said J, **MELMED S**: Remission of acromegaly caused by pituitary carcinoma following surgical excision of GH secreting metastasis detected by 111-indium pentetreotide scan. *J Clin Endocrinol Metab* 81:1628-1633, 1996.
127. Faccenda E, **MELMED S**, Bevan JS, Eidne KA: Structure of the thyrotropin-releasing hormone (TRH) receptor in functional and in clinically non-functioning pituitary adenomas. *Clin Endocrinology* 44: 341-347, 1996.
128. Shimon I, Huttner A, Said J, Spirina OM, **MELMED S**: Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. *J Clin Invest* 97:187-195, 1996.
129. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line: role of stat pathway. *J Clin Invest* 97:1852-1859, 1996.
130. Akita S, Malkin J, **MELMED S**: Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotrophic hormone (ACTH) secretion. *Endocrinology* 137:3140-3143 1996.
131. Wang Z, Song-Guang R, **MELMED S**: Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. *Endocrinology* 137:2947-2953, 1996.
132. Stefana B, Ray DW, **MELMED S**: Leukemia inhibitory factor (LIF) induces differentiation of pituitary corticotroph function: an immuno-neuroendocrine phenotypic switch. *Proc Nat Acad Sci* 93:12502-12506, 1996.
133. Akita S, Conn PM, **MELMED S**: Leukemia inhibitory factor (LIF) induces acute adrenocorticotrophic hormone (ACTH) secretion in fetal rhesus macaque primates: A novel dynamic test of pituitary function. *J Clin Endocrinol Metab* 81:4170-4173, 1996.
134. Shohat M, Tick D, Barakat S. Bu X, **MELMED S**, Rimoin DL: Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. *J Clin Endocrinol Metab* 81:4033-4037, 1996.
135. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, **MELMED S**: Somatostatin receptor subtype specificity in human fetal pituitary cultures: Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone and prolactin regulation. *J Clin Invest* 99:789-798, 1997.
136. Pei L, **MELMED S**: Isolation and characterization of a pituitary tumor transforming gene (PTTG). *Mol Endocrinol*, 11:433-441, 1997.
137. Bousquet C, Ray DW, **MELMED S**: A common proopiomelanocortin binding element mediates leukemia inhibitory factor and corticotropin releasing hormone transcriptional synergy. *J Biol Chem*, 272:10551-10557, 1997.
138. Akita S, Readhead C, Stefanescu L, Fine J, Tampanaru-Sarmesin A, Kovacs K, **MELMED S**: Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adults pituitary function: A model for human pituitary Rathke's cysts. *J Clin Invest*, 99:2462-2469, 1997.
139. Shimon I, Yan X, Ray DW, **MELMED S**: Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. *J Clin Invest*, 100:357-363, 1997.
140. Shimon I, Yan Xinmin, Taylor J., Weiss MH, Culler MD, **MELMED S**. Somatostatin Receptor (SSTR) Subtype-Selective Analogues Differentially Suppress in vitro Growth Hormone and Prolactin in Human Pituitary Adenomas: Novel Potential Therapy for Functional Pituitary Tumors. *J Clin Invest* 100:2386-2392, 1997.

141. Wang Z, **MELMED S**: Identification of an upstream enhancer within a functional promoter of the human leukemia inhibitory factor receptor gene and its alternative promoter usage. J Biol Chem, 272:27957-27965, 1997.
142. Shimon I, **MELMED S**: Structure and function of somatostatin receptors in growth hormone control. Endocrinology 155:S3-S6, 1997.
143. Ren SG, **MELMED S**, Braunstein GD: Decidual leukemia inhibitory factor production and action on human chorionic gonadotropin secretion at different stages of gestation in vitro. Early Pregnancy: Biology and Medicine 3: 102-108, 1997.
144. Shimon I, **MELMED S** Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab 83:174-178, 1998.
145. Bonert V, Seliverstov M, **MELMED S**: Pregnancy in acromegaly: Successful therapeutic outcome. J Clin Endocrinol Metab, 83:727-731, 1998.
146. Shimon I, Hinton DR, Weiss MH, **MELMED S**: Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumor invasiveness. Clin Endocrinol, 48:23-29, 1998.
147. Prezant TR, Levine J, **MELMED S**: Molecular characterization of the MEN-1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab, 83:1388-1391, 1998.
148. Ren S-G, Seliktar J, Li X, Braunstein GD, **MELMED S**: Measurement of leukemia inhibitory factor in biological fluids by radioimmunoassay. J Clin Endocrinol Metab 83:1275-1283, 1998.
149. Chesnokova V, Auernhammer C, **MELMED S**: Murine leukemia inhibitory factor (LIF) gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 139:2209-2216, 1998.
150. Auernhammer C, Chesnokova V, **MELMED S**: Leukemia inhibitory factor (LIF) modulates IL-1 $\beta$  induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 139:2201-2208, 1998.
151. Takeuchi S, Koeffler P, Minton D, Miyoshi I, **MELMED S**, Shimon I: Mutation and expression analysis of the cycline dependent-kinase inhibitor gene p27 KIP1 in pituitary tumors. J Endocrinology 157:337-341, 1998.
152. Auernhammer C, Chesnokova V, Bousquet C, **MELMED S**: Pituitary corticotroph SOCS-3: novel intracellular regulation of cytokine-mediated POMC gene expression and ACTH secretion. Molecular Endocrinol 12:954-961, 1998.
153. **MELMED S**, Jackson I, Kleinberg D, Klibanski A: Current treatment guidelines for Acromegaly. J Clin Endocrinol Metab, 83:2646-2652, 1998.
154. Newman C, **MELMED S**, George A, Torigian D, Duhaney M, Snyder S, et al: Octreotide as primary therapy for acromegaly. J Clin Endocrinol & Metab, 83:3034-3040, 1998.
155. Drange M, **MELMED S**: Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated carcinoid. J Clin Endocrinol Metab, 83:3104-3109, 1998.
156. Shimon I, **MELMED S**: Management of pituitary tumors. Annals of Internal Medicine, 129:472-483, 1998
157. Wang Z, **MELMED S**: Functional map of a placenta specific enhancer of the human leukemia inhibitory factor receptor gene. J Biol Chem, 273:26069-26077, 1998.
158. Shimon I, Yan X, Magoffin DA, Friedman T, **MELMED S**: Intact leptin receptor is selectively expressed in human fetal pituitary and pituitary adenomas and signals human fetal pituitary growth hormone secretion. J Clin Endocrinol Metab, 83:4059-4064, 1998.
159. Yano H, Readhead C, Nakashima M, Ren S-G, **MELMED S**: Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: Neuro-immune endocrine modulation of pituitary development. Molecular Endocrinology, 12:1708-1720, 1998.
160. Zhang X, Horwitz G, Heaney T, Nakashima M, Prezant TR, Bronstein M, **MELMED S**: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas: marker for functional tumor invasiveness. J Clin Endocrinol Metab, 84:761-767, 1999.

161. Zhang X, Horwitz G, Prezant T, Valentini T, Bronstein M, **MELMED S**: Structure, expression and function of human pituitary tumor transforming gene (PTTG). Mol Endocrinol, 13:156-166, 1999.
162. Gadelha MR, Prezant TR, Une KN, Glick RA, Moskal SF, Vaisman M, **MELMED S**, Kineman RD, Frohman LA: Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I (Men-I) gene. J Clin Endocrinol Metab, 84:249-256, 1999.
163. Prezant T, Kadioglu P, **MELMED S**: An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: Evidence for hPTTG family. J Clin Endocrinol Metab, 84:1149-1152, 1999.
164. Auernhammer C, **MELMED S**: Interleukin-11 stimulates POMC gene expression and ACTH secretion in corticotroph cells: evidence for a redundant cytokine network in the HPA axis. Endocrinology, 140:1559-1566, 1999.
165. Bousquet C, **MELMED S**: Critical role for STAT3 in murine pituitary ACTH leukemia inhibitory factor (LIF) signaling. J Biol Chem, 274:10723-10730, 1999.
166. Auernhammer C, Bousquet C, **MELMED S**: Autoregulation of pituitary corticotroph SOCS-3 expression-characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci, 96:6964-6969, 1999.
167. Tran A, Kovacs K, Stefanescu L, Kontogeorgos G, Scheithauer BW, **MELMED S**: Expression of leukemia inhibitory factor in craniopharyngioma. Endo Pathol 10(2): 103-108, 1999.
168. Ren S-G, Seliktar J, Li X, Hershmann J, Braunstein GD, **MELMED S**: In vivo and in vitro regulation of thyroid leukemia inhibitory factor (LIF) marker of hypothyroidism. J Clin Endocrinol & Metab 84:2883-2887, 1999.
169. **MELMED S**: Insulin-like growth factor I – a prototypic peripheral-paracrine hormone? Endocrinology 140:3879-3880, 1999.
170. Bousquet C, Susini C, **MELMED S**: Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 104:1277-1285, 1999.
171. Heaney AP, Horwitz GA, Wang Z, Singson R, **MELMED S**. Early involvement of estrogen-induced pituitary tumor transforming gene (PTTG1) and fibroblast growth factor (bFGF) expression in prolactinoma pathogenesis. Nature Medicine 5:1317-1321, 1999.
172. Drange M, **MELMED S**: Molecular pathogenesis of acromegaly. Pituitary, 2:43-50, 1999.
173. Meisel SR, Shimon I, Edgington TS, **MELMED S**, Cercek B, Shah PK: Leukaemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: a gp130-mediated mechanism. Br J Haematology 107: 747-755, 1999.
174. Drange MR, Fram NR, Bonert VH, **MELMED S**: Pituitary tumor registry: A novel clinical resource. J Clin Endocrinol Metab, 85:168-174, 2000.
175. Wang Z, **MELMED S**: Characterization of the murine pituitary tumor transforming gene (PTTG) gene and its promoter. Endocrinology, 141:763-771, 2000.
176. Heaney A, **MELMED S**: New Pituitary Oncogenes. Endocrine Related Cancer, 7:3-15, 2000.
177. Heaney A, **MELMED S**, Singson R, McCabe CJ, Nelson V, Nakashima M: Expression of pituitary tumor transforming gene in colorectal tumors. Lancet 355:716-719, 2000.
178. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass, von Werder J, **MELMED S**: Criteria for cure of acromegaly: A consensus statement, J Clin Endocrinol Metab, 85:526-529, 2000.
179. Wang Z, **MELMED S**: Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275:7459-7461, 2000.
180. Yu R, Ren S-G, Wang Z, Horwitz G, **MELMED S**: The pituitary tumor transforming gene (PTTG) regulates cells survival and division; evidence from live cell imaging. Mol Endo, 14:1137-1146, 2000.
181. Kontogeorgos G, Patralexis H, Tran A, Kovacs K, **MELMED S**: Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study. Pituitary 2:245-251, 2000.



182. Bonert VH, Zib K, Scarlett JA, **MELMED S**: Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. *J Clin Endocrinol Metab*, 85: 2958-2961, 2000.
183. Maheshwari HG, Herman-Bonert V, Shahinian H, Kovacs K, **MELMED S**: Long acting peptidomergic control of gigantism caused by acidophilic stem cell adenoma. *J Clin Endocrinol Metab*, 85:3409-3416, 2000.
184. Bousquet C, Zatelli MC, **MELMED S**: Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. *J Clin Invest* 106: 1417-1425, 2000.
185. Chesnokova V, **MELMED S**: Leukemia inhibitory factor (LIF) mediates the hypothalamic pituitary adrenal axis response to inflammation. *Endocrinology* 141:4032-4040, 2000.
186. Stefaneanu L, Kovacs K, Thapar K, Horvath E, **MELMED S**, Greenman Y: Octreotide effect on growth hormone and somatostatin subtype 2 receptor mRNAs of the human pituitary somatotroph adenomas. *Endocrine Path* 11:41-48, 2000.
187. Yu R, Heaney AP, Lu W, Chen J, **MELMED S**: Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. *J Biol Chem*, 275:36502-36505, 2001.
188. Ishikawa H, Heaney AP, Yu R, Horwitz G, **MELMED S**: Human pituitary tumor transforming gene (PTTG) induces angiogenesis. *J Clin Endocrinol Metab*, 86:867-874, 2001.
189. Yu R, **MELMED S**: Oncogene activation in pituitary tumors. *Brain Pathology*, 11:328-341, 2001.
190. Rubinek T, Hadani M, Barkai G, **MELMED S**, Shimon I: Prolactin (PRL)-releasing peptide stimulates prolactin secretion from human fetal pituitary cultures and growth hormone release from cultured pituitary adenomas. *J Clin Endocrinol Metab*, 86:2826-2830, 2001.
191. **MELMED S**: Acromegaly and Cancer: not a problem. *J Clin Endocrinol Metab*, 86:2929-34, 2001.
192. Bousquet C, Chesnokova V, Kariagina A, Ferrand A, **MELMED S**: cAMP neuropeptide agonists induce pituitary suppressor of cytokine signaling-3: novel negative feedback mechanism for corticotroph cytokine action. *Mol Endo*, 15:1880-1890, 2001.
193. Wang Z, Yu R, **MELMED S**: Mice lacking pituitary tumor transforming gene (PTTG) show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression and premature centromere division, *Mol Endo* 15:1870-1879, 2001.
194. Auernhammer CJ, **MELMED S**: The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. *J Clin Invest*, 108:1735-1740, 2001.
195. van der Lely A, Hutson K, Trainer PJ, Besser M, Barkan A, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, *Lancet*, 2001.
196. Bode JG, Ludwig S, Freitas CA, Schaper F, Ruhl M, **MELMED S**, Heinrich PC, Haussinger D. The MKK6/p38 mitogen activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6 induced transcription. *Biol Chem* 382:1447-1453, 2001.
197. Ben Shlomo A, **MELMED S**: Growth hormone excess and cancer. *J Anti-Aging Med* 4:373-381, 2001.
198. Heaney A, **MELMED S**: Functional role of estrogen receptor in pituitary tumor pathogenesis, *J Clin Invest*, 109:277-283, 2002.
199. Chesnokova V, Kariagina A, **MELMED S**: Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation. *Am J Physiology*, 282:E1110-E1118, 2002.
201. **MELMED S**, Casanueva F, Cavagnini F, Chanson P, Frohman L, Giordano G, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Pinchera A, Serio M, Vance ML, Vigneri R, Wass J, von Werder K, Giustina A. Guidelines for acromegaly management: a consensus statement. *J Clin Endocrinol Metab*, 87:4054-4058, 2002.
202. Yu R, Song-Guang R, **MELMED S**: Proteasome inhibitors induce apoptosis in GH- and PRL-secreting rat pituitary tumor cells. *Journal of Endocrinology*, 174:379-386, 2002.
203. Heaney AP, Fernando M, Yong W, **MELMED S**: Functional PPAR- $\gamma$  Receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas, *Nature Medicine*, 8:1281-1287, 2002.

204. Stoika, RS, Yu R, **MELMED S**: Expression and function of pituitary tumour transforming gene (PTTG) for T-lymphocyte activation. *British Journal of Haematology*, 119:1070-1074, 2002.
205. Kontogeorgos G, Scheithauer BW, Kovacs KK, Horvath E, **MELMED S**: Growth factors and cytokines in paragangliomas and pheochromocytomas, with a special reference to the sustentacular cells. *Endocrine Pathology*, 13: 192-206, 2002.
206. **MELMED S**, Vance ML, Barkan AL, Bengtsson B-A, Kleinberg D, Klibanski A, Trainer PJ: Current status and future opportunities for controlling acromegaly. *Pituitary*, 5:185-196, 2002.
207. Chesnokova V, **MELMED S**: Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. *Endocrinology* 143:1571-1574, 2002.
208. Ben-Shlomo A, Miklofsky I, Ren S-G, Yong WH, Heaney AP, Culler MD, **MELMED S**: Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells, *J Clin Endocrinol and Metab*, 88:858-63, 2003.
209. Horwitz GA, Miklofsky I, Heaney AP, Ren S-G, **MELMED S**: Human pituitary tumor transformation gene (PTTG1) motif suppresses prolactin expression. *Mol Endo* 17:600-609, 2003.
210. Wang Z, Moro E, Kovacs K, Yu R, **MELMED S**: Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. *Proc Natl Acad Sci* 100:3428-32, 2003.
211. Heaney AP, **MELMED S**: PPAR- $\gamma$  receptor ligands: novel therapy for pituitary adenomas. *J Clin Invest*, 111:1381-8, 2003.
212. Liu N-A, Huang H, Yang Z, Herzog W, Hammerschmidt M, Lin S, **MELMED S**: Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. *Mol Endo*, 17:959-966, 2003.
213. Ren, SG, Kim S, Taylor J, Dong J, Moreau J-P, Culler M, **MELMED S**: Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. *J Clin Endocrinol Metab*, 88:5414-21, 2003.
214. Yu R, Lu W, **MELMED S**: Overexpressed pituitary tumor transforming gene (PTTG) cause aneuploidy in live human cells. *Endocrinology*, 144:4991-4998, 2003.
215. Ren SG, Taylor J, Dong J, Yu R, Culler MD, **MELMED S**: Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. *J Clin Endocrinol and Metab* 88:4239-45, 2003.
216. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, **MELMED S**, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO: Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. *J Clin Endocrinol Metab* 88:4759-67, 2003.
217. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, et al: Diagnosis and treatment of acromegaly complications. *J Endocrinol Invest* 26:1242-47, 2003.
218. **MELMED S**: Mechanisms for pituitary tumorigenesis: the plastic pituitary. *J Clin Invest* 112 (11): 1603-1618, 2003.
219. Abbud RA, Kelleher R, **MELMED S**: Cell specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for POMC expression. *Endocrinology*, 145:867-880, 2004.
220. Bonert VB, **MELMED S** Body mass index determines evoked GH responsiveness in normal health male subjects: Diagnostic caveat for adult GH deficiency. *J Clin Endocrinol Metab*, 89:3397-3401, 2004.
221. Murray RD, Kim K, Ren S-G, Chelly M, Umerhara Y, **MELMED S**: Central and peripheral actions of somatostatin on the growth hormone-insulin-like growth factor-I axis. *J Clin Investigation*, 114:349-356, 2004.
222. Heaney A, **MELMED S**: Molecular targets in pituitary tumors. *Nature Rev Cancer*, 4:285-295, 2004.
223. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns G, **MELMED S**: The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. *J Clin Endocrinol Metab*, 89:3027-3032, 2004.

224. Ben-Shlomo A, Herman-Bonert V, **MELMED S**: Pegvisomant: the role of a growth hormone receptor antagonist in the treatment of acromegaly. *Curr Opin in Endo and Diab*. 11:276-280, 2004.
225. Yu R, **MELMED S**: Pituitary tumor transforming gene: an update. Kontogeorgos G, Kovacs K (eds) in *Molecular Pathology of the Pituitary*. *Front Horm Res*, Basel, Karger, 32:175-185, 2004.
226. Boelaert K, Yu R, Tannahill L, Stratford AL, Khanim FL, Eggo MC, Moore JS, Young LS, Gittos NJ, Franklyn JA, **MELMED S**, McCabe CJ. PTTG's c-terminal PXXP motifs modulate critical cellular processes in vitro. *J Mol Endocrinol* 33:663-77, 2004.
227. Abbud A, Barker EM, Takumi I, Ren SG, Chen DY, Wawrowsky K, **MELMED S**: Early multipotential pituitary focal hyperplasia in the  $\alpha$ -subunit of glycoprotein hormone-driven pituitary tumor transforming gene transgenic mice. *Mol Endo*, 19:1383-91, 2005.
228. Chesnokova V, Kovacs K, Castro A-V, Alon D, **MELMED S**: PTTG hypoplasia in PTTG -/- mice is protective for Rb +/- pituitary tumorigenesis. *Mol Endo*, 19:2371-2379, 2005.
229. Ben-Shlomo A, Wawrowsky KA, Miklovsky I, Ren SG, Taylor J, Culler MD, **MELMED S**: Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of ACTH secretion. *J Biol Chem* 280:24011-21, 2005.
230. **MELMED S**, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. *J Clin Endo Metab*, 90:4405-4410, 2005.
231. **MELMED S**. Pharmacologic treatment of acromegaly. *Medscape Clinical Update* (e-pub), 2005.
232. Akino K, Akita S, Mizuguchi T, Takumi I, Yu R, Wang XY, Roxga J, Demetriou AA, **MELMED S**, Ohtsuru A, Yamashita S. A novel molecular marker of pituitary tumor transforming gene involves in rat liver regeneration. *J Surg Res* 129:142-146, 2005.
233. **MELMED S**, Casanueva F, Cavagnini P, Chanson P, Frohman LA, Laws E, Gaillard R, Ghigo E, Ho K, Kleinberg D, Jacquet P, Lamberts S, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JAH, Giustina A. Consensus statement: medical management of acromegaly. *Eur J of Endo* 153:737-40, 2005.
234. Donangelo I, **MELMED S**: Treatment of acromegaly: future. *Endocrine* 28:123-8, 2005.
235. Donangelo I, **MELMED S**: Pathophysiology of pituitary adenomas. *J Endocrinol Invest* 28:100-105, 2005.
236. Liu N-A, Liu Q, Wawrowsky K, Yang Z, Lin S, **MELMED S**: Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotroph. *Mol Endocrinology*, 20:871-80, 2006.
237. Yu R, Bonert V, Cruz-Soto M, **MELMED S**: Comment: Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism. *Endocrine* 29:119-120, 2006.
238. **MELMED S**: 2004 World Health Organization classification of pituitary tumors: what is new? *Acta Neuropathol (Berl)* 111:78-79, 2006.
239. Gillingwater TH, Wishart TM, Chen PE, Haley JE, Robertson K, MacDonald SH, Middleton S, Wawrowski K, Shipston MJ, **MELMED S**, Wyllie DJ, Skehel PA, Coleman MP, Ribchester RR: The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. *Hum Mol Genet* 15:625-635, 2006.
240. Donangelo I, **MELMED S**: Implication of pituitary tropic status on tumor development. *Front Horm Res* 35:1-8, 2006.
241. Bronstein MD, **MELMED S**: Pituitary tumorigenesis. *Arg Bras Endocrinol Metab* 49:615-625, 2006.
242. Lum PY, Chen Y, Zhu J, Lamb J, **MELMED S**, Wang S, Drake TA, Lusic AJ, Schadt EE: Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. *J Neurochem*, Supplement (97) 1:50-62, 2006.
243. Akita S, Akino K, Ren SG, **MELMED S**, Imaizumi T, Hirano A: Elevated circulating leukemia inhibitory factor in patients with extensive burns. *J Burn Care Res*, 27:221-225, 2006.
244. Ren S-G, **MELMED S**: Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion. *Endocrinology* 147:3936-3942, 2006.

245. Bonert VH, **MELMED S**: Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endo and Metab 2:408-12, 2006.
246. Fraenkel M, Caloyeras J, Ren SG, **MELMED S**: Sex-steroid milieu determines diabetes rescue in pttg-null mice. J Endocrinol 189:519-528, 2006.
247. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, **MELMED S**: PTTG over-expression facilitates pituitary tumor development. Endocrinology 147:4781-4791, 2006.
248. **MELMED S**, Acromegaly. New Engl J Med, 355:2558-2573, 2006.
249. Liu NA, Liu Q, Wawrowsky K, Yang Z, Lin S, **MELMED S**: Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol 20:871-880, 2006.
250. Yu R, Bonert V, Saporta I, Raffel LJ, **MELMED S**: Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol & Metab, 91:5126-5129, 2006.
251. Ben-Shlomo A, **MELMED S**: Skin manifestations in acromegaly. Clinics in Dermatology in Endocrinology and the Skin, Vol. 24, pp. 256-259, 2006.
252. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer C, **MELMED S**: Mechanisms for growth factor-induced pituitary tumor transforming gene-1 (PTTG1) expression in pituitary folliculostellate TtT/GF cells. Mol Endo 20:3321-3335, 2006.
253. Tong Y, Tan Y, Zhou C, **MELMED S**: Pituitary tumor transforming gene interacts with SP1 to modulate G1/S cell phase transition. Oncogene, 26:5596-5605, 2007.
254. **MELMED S**: Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: Another Interesting Protein. J Clin Endocrinol Metab, 92:1617-1619, 2007.
255. Ben-Shlomo A, **MELMED S**: Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endo, 21:2565-2578, 2007.
256. Rubinek T, Wolf I, Chesnokova V, Vlotides G, **MELMED S**: Discordant proliferation and differentiation in pituitary transforming gene-null bone marrow stem cells. Am J Physiol 293:C1082-1092, 2007.
257. Gruszka A, Ren S-G, Dong J, Culler MD, **MELMED S**: Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology, 148:6107-6114, 2007.
258. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, **MELMED S**: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res, 67:10564-10572, 2007.
259. Ben-Shlomo A, **MELMED S**: Drug profile: Pasireotide- a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 10:885-895, 2007.
260. Melmed GY, Yu R, Vlotides G, Ross G, Soraya A, Devlin S, **MELMED S**: Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis". Clin Gastr and Hepat, 6:360-363, 2008. PMID: PMC2696478
261. **MELMED S**: Update in Pituitary Disease, J Clin Endocrinol and Metab 93:331-338, 2008. PMID:18258780
262. Cooper O, Geller J, **MELMED S**: Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endo & Metab, 4:234-238, 2008. PMID: PMC2777809
263. Liu N-A, Ren M, Song J, Rios Y, Wawrowsky K, Ben-Shlomo A, Lin S, **MELMED S**: In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. Developmental Biology, 319:192-200, 2008. PMID: PMC2583244
264. Murray RD, **MELMED S**: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab, 93:2957-2968, 2008. PMID: 18477663
265. Ben-Shlomo A, **MELMED S**: Somatostatin agonists for treatment of acromegaly. Mol and Cell Endocrinol, 286:192-208, 2008. PMID: PMC2697610
266. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren S-G, **MELMED S**: Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res, 68:6377-6386, 2008. PMID: PMC2497431

267. Zhou C, Tong Y, Wawrowsky K, Bannykh S, Donangelo I, **MELMED S**: Oct-1 induces human pituitary tumor transforming gene (hPTTG1) expression in endocrine tumors. Endocrine-Related Cancer, 15:817-831, 2008. PMID:18550719
268. Tong Y, Ben-Shlomo A, Zhou C, Wawrowsky K, **MELMED S**: Pituitary tumor transforming gene (PTTG1) modulates Aurora Kinase A activity. Oncogene 27:6385-95, 2008.
269. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, **MELMED S**: Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 93:3515-3518, 2008. PMID:18611977
270. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, **MELMED S**: Pituitary Society, European Neuroendocrine Association. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endo Invest, 31:820-838, 2008. PMID:18997495
271. Chesnokova V, Zonis S, Kovacs K, BenShlomo A, Wawrowsky K, Bannykh S, **MELMED S**: p21Cip1/Kip1 restrains pituitary tumor growth. Proc Natl Acad Sci 105:17498-17503, 2008.
272. Biller BM, Grossman AB, Stewart PM, **MELMED S**, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462, 2008.
273. Webb SM, Strasburger CJ, Mo D, Harman ML, **MELMED S**, Jung H, Blum WF, Attanasio AF: on behalf of the HypoCCS international Advisory Board. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab, 94:392-399, 2009. PMID: 19001512
274. Carmichael JD, Bonert VS, Mirocha JM, **MELMED S**, The utility of oral glucose tolerance testing (OGTT) for diagnosis and assessment of treatment outcomes in 170 patients with acromegaly. J Clin Endocrinol Metab, 94:523-527, 2009. PMID:19033371
275. Ben-Shlomo A, Zhou C, Pichurin O, Chesnokova V, Liu NA, Culler M, **MELMED S**: Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endo, 23:337-348, 2009. PMCID: PMC2725764
276. **MELMED S**, Barkan A, Chanson P, Clemmons D, Colao A, Grossman A, Ho K, Kleinberg D, Laws E, Molitch M, Schlechte J, Vance ML, Giustina A: Guidelines for acromegaly management: an update, J Clin Endocrinol Metab 94:1509-17, 2009.
277. Arzt E, Chesnokova V, Stalla GK, **MELMED S**: Pituitary adenoma growth: A model for cellular senescence and cytokine action, Cell Cycle 8: 677-682, 2009. PMCID: PMC2710531
278. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, **MELMED S**: Heregulin regulates prolactinoma gene expression, Cancer Res 69:4209-4216, 2009. PMCID: PMC2688701
279. Vlotides G, Chen YH, Eigler T, **MELMED S**: Fibroblast growth factor-2 auto-feedback regulation in pituitary folliculostellate TtT/GF cells, Endocrinology 150:3252-8, 2009. PMCID: PMC2703553
280. **MELMED S**: Acromegaly pathogenesis and treatment. J Clin Investigation, 119:3189-202, 2009. PMCID: PMC2769196
281. Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, **MELMED S**: Differential ligand-mediated pituitary somatostatin receptor subtype signalling: Implications for corticotroph tumor therapy. J Clin Endocrinol Metab, 94:4342-50, 2009. PMCID: PMC2697610.
282. Zhou C, Wawrowsky K, Bannykh S, Gutman S, **MELMED S**: E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol, 23:2000-12, 2009. PMCID: PMC2796149
283. Chesnokova V, **MELMED S**: Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res 71 Suppl 2:82-87, 2009. PMID:19407503

284. Boscaro M, Ludlam WH, Atkinson B, GLusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BMK, Fiindling J, **MELMED S**, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. *J Clin Endocrinol Metab* 94:115-122, 2009.
285. Webb SM, Mo D, Lamberts SWJ, **MELMED S**, Cavagnini F, Giraldi FP, Strasburger CJ, Zimmermann AG, Woodmansee WW on behalf of the International HypoCCS advisory board: Metabolic, cardiovascular and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. *J Clin Endocrinol Metab* 95:630-8, 2010. PMID:20022992
286. **MELMED S**, Cook D, Schopohl J, Goth MI, Lam KSL, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicentre study with a 52 week open extension. *Pituitary* 13:18-28, 2010. PMID: PMC2807598
287. Klibanski A, **MELMED S**, Clemmons DR, Colao A, Cunningham RS, Molitch ME, Vinik AI, Adelman DT, Liebert KJP: The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. *Pituitary*, 13:266-286, 2010. PMID: PMC2913001
288. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts A, Casanueva FF, Trainer P, Ghigo E, Ho K, **MELMED S**: A consensus on criteria for cure of acromegaly. *J Clin Endocrinol Metab*, 95:3141-3148, 2010.
289. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, **MELMED S**: Silent corticogonadotroph pituitary adenomas: clinical and cellular characteristics and long-term outcomes. *Hormones and Cancer*, 1:80-92, 2010. PMID: PMC2921667
290. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y-Y, Hu K, Farrall AJ, **MELMED S**, Biller BMK, and the Pasireotide Acromegaly Study Group: Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. *J Clin Endocrinol Metab*, 95:2781-2789, 2010.
291. Ben-Shlomo A, Wawrowsky K, **MELMED S**: Constitutive activity of somatostatin receptor subtypes, *Methods Enzymol* 484:149-64, 2010. PMID:21036231
292. Yu R, **MELMED S**: Pathogenesis of pituitary tumors. *Prog Brain Res* 182:207-27, 2010. PMID:20541667
293. Chesnokova V, Zonis S, Ben-Shlomo A, Wawrowsky K, **MELMED S**: Molecular mechanisms of pituitary adenoma senescence. *Front Horm Res* 38:7-14, 2010. PMID:20616490
294. Rios Y, **MELMED S**, Lin S, Liu N-A: Zebrafish *usp39* mutation leads to *rb1* mRNA splicing defect and pituitary lineage expansion. *PLoS Genetics*, 7:1271-82, 2011. PMID:18477663
295. **MELMED S**, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH: Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline, *J Clin Endocrinol Metab*, 96:273-288, 2011. PMID:21296991
296. Fukuoka H, Cooper O, Mizutani J, Tong Y, Song-Guang R, Bannykh S, **MELMED S**: HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. *Mol Endocrinol*, 25:92-103, 2011. PMID:21106881
297. Hoffman AR, **MELMED S**, Schlechte J: Patient guide to hyperprolactinemia diagnosis and treatment. *J Clin Endocrinol Metab* 96:35A-6A, 2011. PMID:21296988
298. Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, Toledano Y, Tong Y, Kovacs K, Scheithauer B, **MELMED S**: Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. *PLoS One*, 6(3):e17924, 2011.
299. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, **MELMED S**: Current management practices for acromegaly: an international survey. *Pituitary*, 14:125-33, 2011. PMID: 21213053
300. **MELMED S**: Pathogenesis of Pituitary Tumors. *Nature Reviews Endocrinology*, 7:257-266, 2011.

301. Famini P, Maya MM, **MELMED S**: Pituitary magnetic resonance imaging for sellar and parasellar masses: Ten year experience in 2598 patients. *J Clin Endocrinol Metab*, 96:1633-41, 2011.
302. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, **MELMED S**: Clinical, quality of life and economic value of acromegaly disease control. *Pituitary* 14:284-294, 2011.
303. Liu NA, Jiang H, Fan X-M, Ben-Shlomo A, Wawrowsky K, Lin S, **MELMED S**. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK ) inhibitor. *Proc Natl Acad Sci*, 108:8414-9, 2011.
304. Tong Y, Zhao W, Wawrowsky K, **MELMED S**: PTTG1 attenuates drug-induced cellular senescence. *PLoS One*, 6:e23754, 2011.
305. Tong Y, Zhou J, Mizutani J, Fukuoka H, Ren S-G, Gutierrez-Hartmann A, Koeffler HP, **MELMED S**: CEBPD suppresses prolactin expression and prolactinoma cell proliferation, *Mol Endocrinol* 25:1880-91, 2011.
306. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, **MELMED S**: EGFR as a Therapeutic Target for human, canine, and mouse ACTH-Secreting Pituitary Adenomas. *J Clin Invest*, 121:4712-21, 2011.
307. Tong Y, Zheng Y, Zhou J, Oyesiku NM, Koeffler HP, **MELMED S**: Genomic characterization of human and rat prolactinomas. *J Clin Endocrinol Metab*, 153:3679-3691, 2012.
308. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Kramer WG, Bidlingmaier M, Strasburger CJ, Kleinberg DL, **MELMED S**, Mamluk R. Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. *J Clin Endocrinol Metab*, 97:2362-2369, 2012.
309. Cooper O, **MELMED S**: Subclinical hyperfunctioning pituitary adenomas: the silent tumors. *Best Practice & Research Clinical Endocrinology & Metabolism*, 26:447-460, 2012.
310. Gruszka A, Culler M, **MELMED S**: Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion *in vitro*. *Mol and Cell Endocrinol*, 362:104-109, 2012.
311. Toledano Y, Zonis S, Song-Guang R, Wawrowsky K, Chesnokova V, **MELMED S**: Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. *Endocrinology* 153:5011-5022, 2012.
312. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, **MELMED S**: Meta-analysis on the effect of octreotide on tumor mass in acromegaly. *PLoS One*, 7:e36411, 2012.
313. Chesnokova V, Zonis S, Wawrowsky K, Tani Y, Ben-Shlomo A, Ljubimov V, Mamelak A, Bannykh S, **MELMED S**: Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph-cell adenoma growth. *Mol Endocrinol* 26:2092-103, 2012.
314. Somm E, Bonnet N, Martinez A, Marks PMH, Cadd VA, Elliott M, Toulotte A, Ferrari SL, Rizzoli R, Huppi PS, Harper E, **MELMED S**, Jones R, Aubert ML. A botulinum toxin-derived targeted secretion inhibitor (TSI) inhibits rat GH/IGF-I axis: a novel therapeutic approach for acromegaly. *J Clin Invest* 122:3295-306, 2012.
315. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, **MELMED S**, Sakurai A, Tonelli F, Brandi ML; Endocrine Society: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *J Clin Endocrinol Metab* 97:2990-3011, 2012.
316. Mamelak AN, Carmichael J, Bonert VH, Cooper O, **MELMED S**. Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. *Pituitary*, 16:393-401, 2013.
317. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB, Chipman JJ, **MELMED S**. Prospective safety surveillance of growth hormone (GH) deficient adults: comparison of GH-treated vs. untreated patients. *J Clin Endocrinol Metab*, 98:980-988, 2013.
318. Ghazi AA, Amirbaigloo A, Dezfooli AA, Saadat N, Ghazi S, Pourafkari M, Tirgari F, Dhall D, Bannykh S, **MELMED S**, Cooper O: Ectopic acromegaly due to growth hormone releasing hormone. *Endocrine*, 43:293-302, 2013.

319. **MELMED S**: Update: Idiopathic Adult Growth Hormone Deficiency. *J Clin Endo Metab*, 98:2187-97, 2013.
320. Ben-Shlomo A, Pichurin O, Khalafi R, Zhou C, Chesnokova V, Ren S-G, Liu NA, **MELMED S**. Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis. *Endocrinology* 154:2399-409, 2013.
321. **MELMED S**, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A: A consensus on the diagnosis and treatment of acromegaly complications. *Pituitary* 16:294-302, 2013.
322. Chesnokova V, Zhou C, Zonis S, Tani Y, Ben-Shlomo A, Ren SG, **MELMED S**: Growth hormone is a cellular senescence target in pituitary and non-pituitary cells. *Proc Natl Acad Sci* 110(35):E3331-9, 2013.
323. Petersenn S, Webber D, Farrall A, DeBlock C, **MELMED S**, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao AM, Barkan A. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. *Pituitary*, 17:132-140, 2014.
324. Zhou C, Tong Y, Wawrowsky K, **MELMED S**: PTTG acts as a STATs target gene for colorectal cancer cell growth and motility. *Oncogene* 33:851-61, 2014.
325. Donangelo I, Ren SG, Eigler T, Svendsen C, **MELMED S**: Sca+ murine pituitary adenoma cells show tumor growth advantage. *Endocr Relat Cancer* 21:203-216, 2014.
326. Carmichael JD, Bonert V, Nuno M, Ly D, **MELMED S**: Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. *J Clin Endocrinol Metab*, 99:1825-1833, 2014.
327. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons D, Klibanski A, Van der Lely AJ, Strasburger CJ, Lamberts SW, Ho, Casanueva FF, **MELMED S**: Expert consensus document: A consensus on the medical treatment of acromegaly. *Nat Revs Endocrinol*, 10:243-248, 2014.
328. Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, **MELMED S**: Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. *Am J of Med*, 127:754-762, 2014.
329. Eigler T, Ben-Shlomo A, Zhou C, Khalafai R, Ren SG, **MELMED S**: Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. *Mol Endocrinol*, 28:554-64, 2014.
330. Keeley PW, Zhou C, Lu L, Williams RW, **MELMED S**, Reese BE: Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics. *Proc Natl Acad Sci*, 111:9295-300, 2014.
331. Katznelson L, Laws Jr ER, **MELMED S**, Molitch ME, Utz A, Wass JA: Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*, 99(11):3933-51 2014.
332. **MELMED S**, Bonert V, Fleseriu M, Kleinberg DL: Acromegaly: Assessing the disorder and navigating therapeutic options for treatment. *Endocrine Practice*, 20(1):1-21, 2014.
333. Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VH, Gertych A, Mamelak AN, **MELMED S**: A structural and functional acromegaly classification. *J Clin Endocrinol Metab*, 100:122-31, 2015.
334. Liu X, Kano M, Takako A, Cooper O, Fukuoka H, **MELMED S**: ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. *Endocrinology*, 156:71-79, 2015.
335. **MELMED S**, Brkic V, Bidlingmaier M, Mercado MA, Van der Lely AJ, Blermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein M, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger CJ: Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial. *J Clin Endocrinol Metab*, 100(4):1699-1708, 2015.
336. Zhou C, Jiao Y, Wang R Ren SG, Wawrowsky K, **MELMED S**: STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. *J Clin Invest*, 125(4):1692-1702, 2015.
337. Liu N-A, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, **MELMED S**: Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing Disease. *J Clin Endocrinol Metab*, 100(7):2557-2564, 2015.



338. **MELMED S:** Fertility and Fragrance: Another cause of Kallmann Syndrome. *J Clin Invest*, 125:2275-8, 2015.
339. Herold K, Majzoub J, **MELMED S**, Pendergrass M, Schlumberger M: Endocrinology research-reflecting on the past decade and looking to the next. *Nat Rev Endo*, 11:672-80, 2015.
340. Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Truong Thanh X-M, Sert C, Houchard A, Guillemin I, **MELMED S**. The Sagit Investigator Group. SAGIT: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. *Pituitary* 19(1):39-49, 2016.
341. **MELMED S:** New therapeutic agents for acromegaly. *Nat Rev Endo*, 12(2):90-8, 2016.
342. **MELMED S:** Pituitary Medicine: from discovery to patient-focused outcomes. *J Clin Endocrinol Metab*, 101(3):769-77, 2016.
343. Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonash KT, Mallick J, Gertych A, Shimon I, Ram Z, **MELMED S**, Stern N. Treatment of clinically and non-functioning pituitary adenomas with dopamine agonists. *Eur J Endocrinol* 175(1):63-72, 2016.
344. Chesnokova V, Zonis, Zhou C, Recouvreux V, Ben Shlomo A, Araki T, Barrett R, Workman M, Wawrowky K, Ljubimov VA, Uhart M, **MELMED S:** Growth hormone is permissive for neoplastic colon growth. *Proc Natl Acad Sci USA* 113(23):E3250-9, 2016.
345. Christiansen JS, Bäckeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Casanueva FF, Chason P, Chatelain P, Choong CS, Clemmons DR, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. *Eur J of Endocrinology* 174(6):C1-8, 2016.
346. Fleseriu M, Hashim I, Karavitaki N, **MELMED S**, Murad MH, Salvatori R, Samuels M. Hormonal replacement in panhypopituitarism: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*, 2016.

#### **PEER-REVIEWED (SUBMITTED)**

1. Araki T, Liu NA, Tone Y, Ben-Shlomo A, Heltsley R, Cuevas-Ramos D, Cooper O, Tone M, **MELMED S:** E2F1-mediated human proopiomelanocortin gene expression: a therapeutic target for ectopic Cushing's syndrome.
2. Bonert V, Mirocha J, Wu Z, Carmichael J, Mamelak A, Perez DA, Clarke NJ, Reitz RE, McPhaul MJ, **MELMED S.** Accuracy of IGF-I mass spectrometry vs. immunometric assays: a prospective clinical validation study.
3. Cooper O, Bonert V, Moser F, Mirocha J, **MELMED S:** Altered pituitary gland structure and function in posttraumatic stress disorder.

#### **LETTERS TO THE EDITOR**

1. **MELMED S:** Radiotherapy for Acromegaly. *N Eng J Med* 323:612-613, 1990 (letter).
2. **MELMED S**, Ezzat S: Colonic Polyps in Acromegaly (letter). *Ann Int Med* 115:232-233, 1991.
3. **MELMED S:** Letter from the United States. *The Endocrinologist* 48:13, 1998.
4. Giustina A, **MELMED S:** Acromegaly Consensus: The next steps. *J Clin Endocrinol Metab* 88:1913-1914, 2003.
5. **MELMED S:** Acromegaly. *N Engl J of Med*, 356:1274-1276, 2007.

#### **REVIEWS-PEER REVIEWED**

1. Morley JE, **MELMED S:** Gonadal dysfunction in systemic disorders. *Metabolism* 28:1051, 1979.
2. **MELMED S**, Braunstein GD, Horvath E, Ezrin C, Kovacs K: Pathophysiology of acromegaly. *Endocrine Reviews* 4:271-290, 1983.

3. **MELMED S**: Control of prolactin synthesis and secretion. Sem Reprod Endocrinol 2:1-8, 1984.
4. **MELMED S**, Chang J, Braunstein GD, Becker D: Growth hormone and prolactin-secreting pituitary tumors. Ann Intern Med 105:238-253, 1986.
5. **MELMED S**, Fagin JA: Acromegaly update: Etiology, Diagnosis and Management. West J Med 146:328-336, 1987.
6. **MELMED S**: Acromegaly. New Eng J Med 322:966-977, 1990.
7. Ezzat S, **MELMED S**: The role of growth factors in the pituitary. J Endocrinol Invest 13:691-698, 1990
8. Ezzat S, **MELMED S**: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol and Metab 72:245-249, 1991.
9. Ezzat S, **MELMED S**: Acromegaly: Etiology, Diagnosis and Management. Comprehensive Therapy 17:31-35, 1991.
10. Greenman Y, **MELMED S**: Diagnosis and management of nonfunctioning pituitary tumors. C.H. Coggins (Ed.), Ann Rev of Med, Vol. 47:95-106, 1996.
11. **MELMED S**, Ho K, Thorner M, Klibanski A, Reichlin S: Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab, 80:3395-3402, 1995.
12. **MELMED S**: Unwanted effects of growth hormone excess in the adult. J Pediatr Endocrinol 9:369-374, 1996.
13. **MELMED S**: Molecular pathophysiology of acromegaly. Acta Pediatr Scan 417:45-48, 1996
14. Shimon S, **MELMED S**: Genetic basis of endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab, 82:1675-1681, 1997.
15. **MELMED S**: gp130-related cytokines and their receptors in the pituitary. Trends in Endocrinol and Metab 8(10):391-397, 1998.
16. **MELMED S**: Structure and function of the dopamine receptor. Endocrinologist 7:385-389, 1997.
17. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor regulates proopiomelanocortin transcription. Proc New York Acad of Sci, 17:189-202, 1997.
18. Klibanski A, Ho K, Freda PU, Clemmons DR, Barkan AL, Kleinberg DL, Trainer PJ, Swearingen B, Molitch ME, Wass JAH, Thorner MO, **MELMED S**, Strasburger CJ, Frohman LA. State-of-the-art strategies for the diagnosis and management of acromegaly. The Endocrinologist 2001 11:223-232.
19. Ray D, **MELMED S**: Pituitary cytokine and growth factor expression and action. Endocrine Reviews 18:206-228, 1997.
20. Auernhammer C, **MELMED S**: Leukemia inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews, 21:313-345, 2000.
21. Prezant TR, **MELMED S**: Molecular pathogenesis of pituitary tumors in Current Opinion in Endocrinology and Diabetes. 9:61-78 2002.
22. Chesnokova V, **MELMED S**: Neuro-immuno-neuroendocrine modulation of the HPA axis by gp130 signaling molecules. Endocrinology, 143:1571-1574, 2002.
23. Turner HE, Harris AL, **MELMED S**, Wass JA: Angiogenesis in endocrine tumours. Endocrine Reviews, 24:600-632, 2003.
24. Ben-Shlomo A, **MELMED S**: The role of pharmacotherapy in peri-operative management of patients with acromegaly. J Clin Endocrinol Metab, 88:963-8, 2003.
25. Vlotides G, Eigler T, **MELMED S**: Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endo Rev, 28:165-186, 2007.
26. Ben-Shlomo A, **MELMED S**: Pituitary somatostatin receptor signaling. Trends in Endocrinol and Metab, 21:123-133, 2010. PMID: PMC2834886
27. Chesnokova V, **MELMED S**: Pituitary senescence: The evolving role of Pttg. Mol Cell Endocrinol, 326:55-59, 2010. PMID: PMC2906651
28. Ljubimov V, Vlotides G, Zhou C, Yu R, **MELMED S**: Pttg1. UCSD-Nat Mol Pages, 2011.
29. Cooper O, Vlotides G, Fukuoka H, Greene MI, **MELMED S**: Expression and function of pituitary ErbB receptors and ligands. Endocr Related Cancer, 18:R197-R211, 2011.
30. **MELMED S**: Pituitary Tumors. Ben-Shlomo A & Fleseriu M (Eds): Endo Metab Clin of No Am, 2014.

## EDITORIALS

1. **MELMED S**, Braunstein GD: Bromocriptine and pleuropulmonary disease. Arch Int Med 149:258, 1989.
2. Herman V, **MELMED S**: Clonality of endocrine tumors. Endocrine Pathology 2:61-63, 1991.
3. Prager D and **MELMED S**: Insulin and insulin-like growth factor I receptors: Are there functional distinctions? Endocrinology 132:1419-1420, 1993.
4. Drange M, **MELMED S**: To sleep perchance to eat. J Clin Endo Metab, 82:1311-1312, 1997.
5. **MELMED S**: Fond Farewell. Endocrinology 139:821, 1998.
6. **MELMED S**: Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab (Editorial), 83:3409-3410, 1998.
7. **MELMED S**: The immuno-neuroendocrine interface. J Clin Invest, 108:1563-1566, 2001.
8. **MELMED S**: Supplemental growth hormone in healthy adults: the endocrinologist's responsibility (Editorial). Nature Clin Practice Endo & Metab 2:1, 2006.

## TEXTBOOKS

1. Robbins R and **MELMED S** (eds): Acromegaly: A century of scientific and clinical progress, Plenum Press, NY, 1987.
2. Draznin B, **MELMED S**, Le Roith D: Molecular & Cellular Biology of Diabetes Mellitus, A. Liss, N.Y., 1988:  
Vol I - Insulin Secretion  
Vol II - Insulin Action  
Vol III - Complications
3. **MELMED S** and Robbins R: Current issues in Endocrinology and Metabolism: Molecular and Clinical Advances in Pituitary Disorders, Blackwell Scientific Publications, Boston, 1991.
4. **MELMED S**: Acromegaly. Endo & Metab Clinics of No. America (Guest Editor), WB Saunders, Vol. 21:3, 1992.
5. **MELMED S** (ed): Molecular and Clinical Advances in Pituitary Disorders: the Proceedings of the 3rd International Pituitary Congress, Marina Del Rey, CA, 1993.
6. **MELMED S**: The Pituitary. Blackwell, Boston, 1995; 2000 2<sup>nd</sup> Edition.
7. **MELMED S**: Oncogenesis and Molecular Biology of Pituitary Tumors, Karger Publications, Switzerland, 1996.
8. Conn P.M. and **MELMED S** (eds): Endocrinology: Basic and Clinical Principles, Humana Press, Inc., Totowa NJ, 1997.
9. **MELMED S**: Hormone Action: Basic and Clinical Aspects, Biomedica 2000.
10. Baxter J, New M and **MELMED S** (eds): Genetics in Endocrinology by Lippincott-Raven Publishers, 2001.
11. Burger HG, Loriaux DL, Marshall JC, **MELMED S**, Odell WD, Potts W, Rubenstein AH: 4<sup>th</sup> Edition, Endocrinology. Vols I, II, and III DeGroot LJ, Jameson JL (Eds), WB Saunders, PA 2001; 5<sup>th</sup> Edition, 2005.
12. **MELMED S** and Conn PM (Eds): 2<sup>nd</sup> Edition, Endocrinology: Basic and Clinical Principles, Humana Press, 2005.
13. Kronenberg H, Larsen R, **MELMED S**, Polonsky K (eds): Williams Textbook of Endocrinology (Saunders), 10<sup>th</sup> Edition, 2002; 11<sup>th</sup> Edition 2006.
14. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 5<sup>th</sup> Edition, Elsevier Publishers, 2006.
15. **MELMED S**, Rochefort H, Chanson P, Christen Y (Eds): Research and Perspectives in Endocrine Interactions: Hormonal Control of Cell Cycle, Springer-Verlag 2006.

16. Kronenberg HM, **MELMED S**, Polonsky KS, Larsen PR (Eds): Williams Textbook of Endocrinology, 11<sup>th</sup> Edition, Elsevier, 2008.
17. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 6<sup>th</sup> Edition, Elsevier Publishers, 2010.
18. **MELMED S**, Polonsky KS, Larsen PR, Kronenberg HM (Eds): Williams Textbook of Endocrinology, 12<sup>th</sup> Edition, Elsevier, 2011.
19. **MELMED S**: The Pituitary. Elsevier Academic Press, 3<sup>rd</sup> Edition, 2011.
20. **MELMED S**: Encyclopedia of Human Biology (3<sup>rd</sup> Edition), Elsevier; Editor (Endocrine), 2013.
21. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 7<sup>th</sup> Edition, Elsevier Publishers, 2015.
22. **MELMED S**, Polonsky KS, Larsen PR, Kronenberg HM (Eds): Williams Textbook of Endocrinology, 13<sup>th</sup> Edition, Elsevier Publications, 2016.

#### NON-PEER REVIEWED

1. **MELMED S**: Acromegaly update. 38th Annual Endocrine Society Postgraduate Assembly, Los Angeles, 1986 (presented).
2. **MELMED S**: Pituitary Tumors: Medical Management. Advances in Neuroophthalmology 18th Jules Stein Eye Institute Postgraduate Seminar, p 41, 1987.
3. **MELMED S**: Medical Management of Pituitary Tumors. 39th Annual Endocrine Society Postgraduate Assembly, San Francisco 1987.
4. **MELMED S**: Medical Management of Pituitary Tumors. Audio-Digest 25:20, 1987.
5. **MELMED S**: Use of Somatostatin in the Management of Pituitary and Extrapituitary Acromegaly. Peptidomimetic Therapy: A novel approach to Endocrine and Gastrointestinal Diseases, San Francisco, 1988 (presented).
6. **MELMED S**: Use of somatostatin in acromegaly. Peptidomimetic Therapy, Baylor University, Houston, 1988 (presented).
7. **MELMED S**: Peptide Therapy for Pituitary Tumors. Peptide Therapy. 1(4): 10-11, 1989.
8. **MELMED S**: Management of growth hormone hypersecretion. Endocrine Society 42nd Postgraduate Assembly, 1990.
9. **MELMED S**: Evidence for an intrinsic cell mutation in pituitary tumorigenesis: Techniques, Results and Perspectives. 4th Meeting of the International Pituitary Pathology Club, Vaison La Romaine, France, 1990.
10. **MELMED S**: Physician's Dilemma: The management of patients with pituitary tumors and acromegaly. Preliminary results of a multi-center trial with octreotide acetate: Clinical activity. The Endocrine Society Meeting, Washington, DC, 1991.
11. Sassolas G, **MELMED S**: Symposium: Basic sandostatin research. Metab Clin and Exp 41:11-16, 1992.
12. **MELMED S**: Recent advances in Somatostatin Basic Research: Action of somatostatin on the GH/IGF-I axis: new advances. Satellite Symposium, Sandostatin, State-of-the-art, Monte Carlo, 1991 (presented).
13. **MELMED S**: Pathophysiology of acromegaly. 10th Spanish Endocrine Congress Meeting, Santiago de Compostela, Spain, 1991 (presented).
14. **MELMED S**. Acromegaly: Therapeutic Options in Endocrine Society Postgraduate Assembly Mtg, 1993.
15. Prager D, Yamasaki H, **MELMED S**: Pituitary IGF-I receptor structure function in Proceedings of 3rd International Pituitary Congress pp. 127-134, 1993.
16. Pei L, Prager D, Scheihauer B, **MELMED S**, Herman V. Molecular characterization of pituitary tumors in Proceedings of 3rd International Pituitary Congress pp. 21-28, 1993.
17. **MELMED S**, Treatment of Acromegaly in Lifetime Medical Television by Alpha Telecommunications (video), May-July 1993.

18. **MELMED S.** Pathophysiology of acromegaly: a review of the current state of knowledge in Acromegaly: Therapeutic Strategies by Excerpta Medica, 1993.
19. **MELMED S.** Comprehensive Management of Acromegaly. Metabolism, Vol 43 pp. 1-5, 1994.
20. **MELMED S:** Acromegaly: Modern Diagnosis and Therapy. Postgraduate course in Clinical Endocrinology, Massachusetts General Hospital-Harvard Medical School, 1995.
21. **MELMED S:** Unwanted effects of growth hormone excess in the adult. Growth Symposium, Santiago de Compostela, 1995.
22. **MELMED S:** Acromegaly in Somatostatin Analogs: Basic and clinical perspectives, Sorrento, Italy 1995.
23. **MELMED S:** Treatment of Acromegaly. UpToDate in Medicine, Vol. 5, 1996; 1998, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012.
24. **MELMED S:** Clinical manifestations of Acromegaly. UpToDate in Medicine, Vol. 5, 1996; 1998, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012.
25. **MELMED S:** Diagnosis of Acromegaly. UpToDate in Medicine, Vol. 5, 1996; 1998, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012.
26. **MELMED S:** Physiology of growth hormone. UpToDate in Medicine, Vol 5, 1996, 1998, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012.
27. **MELMED S:** Definition and pathogenesis in Acromegaly on CD-Rom: Recent update on Acromegaly. Eds A. Giustina, JD Veldhuis, 1999.
28. **MELMED S:** Pharmacotherapy of Acromegaly. Clinical Endocrinology Update, Syllabus 109-114, 1999.
29. **MELMED S:** Is it time for new indications for GH? Endocrine Today, Clinical news on diabetes and endocrine disorders article, 2007.
30. **MELMED S:** Challenges in life sciences and health systems in 21st Century. RECOOP HST Association Mtg in Croatia, 2014
31. **MELMED S:** Uncommon knowledge: Advancing medical therapy of pituitary tumors. Basic Researcher Perspective. Endocrine News Magazine, October 2014, pp 50-55.
32. **MELMED S:** Letter from America Endocrinology: “Sine Stercore Tauri”. The Endocrinologist Issue 114/15 p. 17, 2014.

### BOOK CHAPTERS

1. **MELMED S,** Hershman JM: The Thyroid and Aging. pp 33-54. In: Endocrine Aspects of Aging. Korenman S. (Ed.), Elsevier, Science Publishing Co., New York, 1982.
2. **MELMED S:** Control of prolactin synthesis and secretion in Seminars in Reproductive Endocrinology, 2:1-8, 1984.
3. **MELMED S:** Human growth hormone gene regulation in somatotroph tumors. Acromegaly Centennial; Plenum Press, NY, 1987.
4. **MELMED S,** Braunstein GD: Endocrine dysfunction in amyotrophic lateral sclerosis. Neurologic Clinics Feb 1987 pp 33-42.
5. **MELMED S:** Ectopic Pituitary and Hypothalamic Hormone Syndromes. Endocrinology & Metabolism Clinics of North America. W.B. Saunders Company, Sept 1987.
6. **MELMED S:** Feedback regulation of growth hormone secretion in the Brain as an Endocrine Organ eds Cohen M, Foa P: Springer Verlag, NY 1988.
7. **MELMED S:** Growth factor regulation of pituitary function. in Neuroendocrine Perspectives eds. E.E. Muller and R.M. and R.M. Macleod, Springer Verlag NY, 1988.
8. **MELMED S:** Oncogenes and the Thyroid in Thyroid Today (ed) J. Oppenheimer, Vol 11, January 1988.
9. Fagin J, Morita S, **MELMED S:** Cellular Pathophysiology of prolactinomas in Prolactin-related Disorders. RE Blackwell and RJ Chang (eds), MacMillan, NJ, 1987.

10. Prager D, **MELMED S**: Insulin regulation of Growth Hormone Gene Expression in Draznin B, Melmed S, LeRoith D, (eds) Molecular & cellular biology of diabetes mellitus, A. Liss NY, 1988 pp 163-173.
11. **MELMED S**, Morita S: Triiodothyronine regulation of GH secretion: additive effects of retinoic acid. Proceedings Nagasaki, International Symposium on Graves Disease ed S. Nagasaki.
12. **MELMED S**, Braunstein GD: Diseases of hypothalamus and pituitary in Stein's Textbook of Internal Medicine, 3rd Edition, Little Brown, 9:2141-2155, 1989.
13. Festoff BW, **MELMED S**, Smith R: Therapeutic trial of recombinant human growth hormone in amyotrophic lateral sclerosis, Advances in Neuromuscular Diseases p 117-126, 1989.
14. **MELMED S**, Prager D, Fagin J: Feedback regulation of growth hormone gene expression by insulin-like growth factor I. Molecular and Cellular Biology of Insulin-like Growth Factors and their Receptors by D. LeRoith and M. K. Raizada (eds) Plenum Publishing Co., pp. 57-72, 1988.
15. Smith RA, Jacoby S, Festoff B, Peterson L, **MELMED S**, Molnar G, Sherman B, and Frane J: The Influence of compliance and other human factors on ALS treatment trials. In: Progress in Clinical Trials. Amyotrophic Lateral Sclerosis. F.C. Rose, Ed., Demos Publications, New York, 1990, pp 1-14.
16. **MELMED S**: Hereditary endocrine tumors in Current Therapy in Endocrinology and Metabolism. Ed. W. Bardin, Mosby, NY pp. 496-498, 1990.
17. Ezzat S, **MELMED S**: Pituitary Tumors in the Elderly by J Morley, S Korenman (eds), Blackwell Scientific Publications. Geriatric Endocrinol, pp. 58-69, 1990.
18. **MELMED S**, Prager D: Molecular Biology of the Endocrine System K. Kovacs & S. Asa (eds) Endocrine Pathology, Blackwell Scientific Publications, NY, Vol 1 pp. 124-142, 1991.
19. **MELMED S**: Acromegaly. Rakel, Conn's Current Therapy, Pub: W.B. Saunders Company, pp. 565-568, 1991.
20. Herman V, Fagin J, Gonsky R, Namba H, Weiss M, Becker D, **MELMED S**: Clonal origin of human pituitary tumors and evidence for transforming activity in Molecular and Clinical Advances in Pituitary Disorders, Blackwell Scientific, pp 247-252, 1991.
21. **MELMED S**: Extra-pituitary Acromegaly. Ed. W. Daughaday, Endocrinology and Metabolism Clinics of North America, pp. 507-518, 1991.
22. **MELMED S**, Herman VS, Prager D, Yamasaki H, Gonsky R, Fagin J: Pituitary adenomas: New trends in basic and clinical research: Role of growth factors in regulation of pituitary hormone production and in the pathogenesis of pituitary tumors. Elsevier Science Publishing Co., pp. 123-130, 1991.
23. **MELMED S**: Etiology of pituitary acromegaly. Endo & Metab Clinics of No. America, WB Saunders, pp. 539-551, 1992.
24. **MELMED S**: Pathogenesis of pituitary tumors in Molecular Genetics of Nervous Tumors by A. Levine and H. Schmidek (eds), pp. 255-263, 1993.
25. **MELMED S**: Acromegaly in Endocrine Tumors by E. Mazzaferri and N. Samaan (eds) published by Blackwell Scientific Publications, 1993.
26. Prager D, **MELMED S**: Somatotroph IGF-I signalling in Role of IGF-I in the nervous system. D. LeRoith (ed) NY Academy of Sciences, 1993.
27. **MELMED S**. Hereditary endocrine tumors in Current Therapy in Endocrinology and Metabolism, Mosby, 1993, Philadelphia.
28. **MELMED S**. General aspects of the management of pituitary tumors by surgery or radiation therapy in DeGroot's Textbook of Endocrinology, WB Saunders Company, Philadelphia, 1993.
29. **MELMED S**. Tumor mass effects of lesions in the hypothalamus and pituitary in DeGroot's Textbook of Endocrinology, WB Saunders Company, Philadelphia, 1993.
30. **MELMED S**. Molecular mechanisms of tumor formation in hereditary and sporadic tumors of the men I type: pituitary neoplasia in Endocrinology and Metabolism Clinics of North America, R. Gagel (ed), 1993.
31. **MELMED S**, Braunstein GD: Disorders of the hypothalamus and anterior pituitary in Stein's Textbook of Internal Medicine, 4th Edition, Little Brown, J.H. Stein (ed), pp 1773-1788, 1993.

32. **MELMED S.** Molecular mechanisms of pituitary tumorigenesis in The Pituitary, H. Imura (ed), Raven Press, 1994.
33. **MELMED S.** Octreotide stimulates insulin-like growth factor (IGF) binding protein-1: A novel mechanism of drug action in acromegaly in Seminars in Oncology, L. Kvols, T. O'Dorisio (eds), WB Saunders Company, 1994.
34. Prager D, **MELMED S.** Mechanisms for insulin-like growth factor I regulation of growth hormone secretion. B B Bercu and R F Walker (eds) Growth Hormone II: Basic and Clinical Aspects, pp. 73-84, 1994.
35. Asa SL, Kovacs K, **MELMED S:** The hypothalamic-pituitary axis. S. Melmed (ed.) in The Pituitary by Blackwell Scientific, 1994.
36. Herman-Bonert VS, Prager D, **MELMED S:** Growth Hormone. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
37. **MELMED S:** Acromegaly. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
38. Greenman Y, **MELMED S:** TSH secreting pituitary tumors. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
39. **MELMED S:** Pituitary Neoplasia. In Multiple Endocrine Neoplasia. Endo and Metab Clinics of North America, Vol 23:81-92, 1994.
40. **MELMED S.** Growth hormone in Reproductive Endocrinology, E. Adashi (ed) by Raven Press, 1995.
41. **MELMED S:** Overview of growth hormone and IGF-I effects on intermediary metabolism and bone. MR Blackman, J Roth, SM Harman and JR Shapiro (eds.) in GHRH, GH, and IGF-I Basic and Clinical advances by Springer-Verlag, 1995.
42. Herman V, **MELMED S:** Acromegaly in Current Diagnosis (Vol. 9). RB Conn, WZ Borer, JW Snyder (Editors), 1995.
43. **MELMED S.** Anterior Pituitary in Current Practice of Medicine S. Korenman (ed), Philadelphia, 1996.
44. Pei L, **MELMED S:** Oncogenesis and molecular biology of pituitary tumors, S. Melmed (ed), Karger Publications, 1995.
45. **MELMED S**, Yamashita S, Yamasaki H, Fagin J, Namba H, Yamamoto H, Weber M, Morita S, Webster J, Prager D: IGF-I receptor signalling lessons from the somatotroph in Recent Progress in Hormone Research, PM Conn (Ed), Vol. 51 1996.
46. Shimon I, **MELMED S:** Anterior Pituitary Hormones in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds.), 1995.
47. Greenman Y, **MELMED S:** Somatostatin receptor subtypes in pituitary tumors in Oncogenes and molecular biology of pituitary tumors, S. Melmed (Ed), Karger, 1995.
48. Pei L, **MELMED S:** Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 1995.
49. Herman V, **MELMED S:** Acromegaly in Current Diagnosis, RB Conn, et al (Eds) 9<sup>th</sup> Edition, 1996.
50. **MELMED S:** Molecular pathogenesis of somatotroph adenomas in Pituitary Adenomas, Elsevier, pp. 13-20, 1996.
51. Shimon I, **MELMED S:** Acromegaly: Differential diagnosis and treatment in Pituitary Disease: Diagnosis and Treatment, Wierman ME (Ed), 1997.
52. **MELMED S:** Pituitary function and neoplasia in Principles of Molecular Medicine Textbook, L Jameson (Ed), Human Press, NJ, pp 443-449, 1998.
53. **MELMED S:** Acromegaly Method in Conn's Current Therapy. R. Rakel (Ed), 1998.
54. **MELMED S:** Acromegaly in Metabolism Clinical and Experimental, 45:51-52, 1996.
55. Drange M, and **MELMED S:** IGFs in the evaluation of acromegaly. In Contemporary Endocrinology. The IGF System: Molecular Biology, Physiology, and Clinical Applications, RG Rosenfield & CT Roberts (ED), Humana Press, pp 699-720, 1999.
56. Shimon I, and **MELMED S:** Diagnosis and treatment of pituitary disease. Weitzer (ED) in Psychotherapy & Psychosomatics, 67:119-124, 1998.

57. Shimon I, **MELMED S**: Pathogenesis and molecular biology of pituitary tumors in Pituitary Tumors, Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (Eds), Humana Press 1998.
58. Prezant T, **MELMED S**: Pituitary oncogenes in Epidemiology, Pathogenesis and Management of pituitary tumors (Ed) SM Webb, pp 81-93, BioScientifica Limited Bristol, UK, 1998
59. Shimon I, **MELMED S**: Pituitary tumor pathogenesis in Genetics in Endocrinology. Baxter J, Melmed S, New M (Eds), 1998.
60. Drange MR, **MELMED S**: Acromegaly: Definition and pathogenesis in Acromegaly on CD-ROM. A. Giustina (Ed), 1998.
61. Drange MR, **MELMED S**: Etiopatogenia de la Acromegalia in Libro De La Acromegalia. S. Webb (Ed), 1998.
62. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor regulates proopiomelanocortin transcription in Neuroimmunomodulation: Molecular aspects, integrative systems, and clinical advances, (Ed) McCann, SM. Annals of The New York Academy of Sciences. 840:162-173, 1998.
63. Shimon I, **MELMED S**: Hypothalamic involvement in disorders of pituitary hormone secretion in Neuroendocrinology in Physiology and Medicine (Eds) Conn, PM and Freeman ME, 1998.
64. **MELMED S**, Braunstein GD: Disorders of the hypothalamus and anterior pituitary in Stein's Textbook of Internal Medicine 5<sup>th</sup> Edition. St. Louis, Mosby pp 1773-1788, 1998.
65. **MELMED S**: Pathogenesis of pituitary tumors in Advances in Pituitary Tumor Therapy. Endocrinology and Metabolism Clinics of North America, 28:1-12, 1999.
66. Auernhammer CJ, Bousquet C, Chesnokova V, **MELMED S**: Leukemia inhibitory factor-new mechanisms for ACTH regulation in Regulation of Pituitary Hormone Secretion, P Beck-Peccoz (Ed). BioScientifica Ltd., Bristol, 1999.
67. Heaney AP, **MELMED S**: Pituitary tumour transforming gene: a novel factor in pituitary tumour formation. Bailliere's Clinical Endocrinology and Metabolism. 13:367-380, 1999.
68. **MELMED S**, Auernhammer C: gp130-related cytokines in Principles of Molecular Regulation, (Eds) PM Conn and Means AR, pp 115-132, 2000.
69. **MELMED S**: Growth hormone in New World Health, Sterling Publications, 2000.
70. Shimon I, **MELMED S**: Pathogenes and molecular biology of pituitary tumors in Diagnosis and management of pituitary tumors. Thapar K, Kovacs K, Scheithauer B, Lloyd RV (Eds), Human Press, 2000.
71. Prezant T, **MELMED S**: Pathogenesis of pituitary tumors in Comprehensive Clinical of Endocrinology 3<sup>rd</sup> Edition, Harcourt by Besser & Thorner (Eds), 2001.
72. Ben-Shlomo A, **MELMED S**: Acromegaly in Neuroendocrinology, Endocrinology and Metabolism Clinics of North America Series, Klibanski A (Ed), pp. 565-583, 2001.
73. Heaney AP, **MELMED S**: Etiology of Pituitary Tumors for Pituitary Adenomas, in Pituitary Disease of Endocrine Update. Sheperd M (Ed), 2001.
74. Bonert VH, **MELMED S**: Pregnancy and Acromegaly in Pituitary Tumors in Pregnancy, Bronstein M (Ed), pp. 109-121, 2001.
75. **MELMED S**: Disorders of the anterior pituitary and hypothalamus in 15<sup>th</sup> Edition Harrison's Principles of Internal Medicine. Braunwald, Fauci, Kasper, Hauser, Longo, Jameson (Eds), pp. 2029-2052, 2001.
76. **MELMED S**: Evaluation of pituitary masses in De Groot L. and Jameson J (eds): Endocrinology, 4<sup>th</sup> Edition (Saunders) pp 282-288, 2001.
77. **MELMED S** in Neuroendocrinology and Pituitary Gland: Acromegaly in De Groot L. and Jameson J (eds): Endocrinology, 4<sup>th</sup> Edition (Saunders) pp 300-312, 2001.
78. Herman-Bonert V, **MELMED S**: Growth hormone in Reproductive Endocrinology, Surgery and Technology, Adashi, Rock and Rosenwaks (Eds), Raven Press, The Pituitary 2<sup>nd</sup> Edition, 2001.
79. Wass J, Lamberts S, **MELMED S**: Long-term treatment strategies for acromegaly in Handbook of Acromegaly, J Wass (Eds), BioScientifica, Ltd in UK, pp 79-83, 2001.
80. Wass J, **MELMED S**, Turner HE: Future areas of research in acromegaly in Handbook of Acromegaly, J Wass (Eds), BioScientifica, Ltd in UK pp. 87-89, 2001.



81. Heaney A, **MELMED S**: Molecular pathogenesis of pituitary tumors in Oxford Textbook of Endocrinology, Wass & Shalet (Eds), 2002.
82. Abbud R, **MELMED S**: SOCS: Suppressors of cytokine signaling. In The Encyclopedia of Molecular Medicine, Ed. Thomas E. Creighton, Wiley & Sons, Inc., 2002.
83. **MELMED S**: Anterior Pituitary in Williams Textbook of Endocrinology, 10<sup>th</sup> Edition, Larsen, Kronenberg, Melmed & Polonsky (Eds), Harcourt Hlth Sci, 2002.
84. **MELMED S**: Acromegaly in The Pituitary 2<sup>nd</sup> Edition, Blackwell Sciences, 2002.
85. Prezant T, **MELMED S**: Pathogenesis of pituitary tumors. Comprehensive Clinical Endocrinology, 3<sup>rd</sup> Edition, Besser M & Thorner M (Ed), 2002.
86. Greenman Y, **MELMED S**: TSH-secreting tumors in The Pituitary 2<sup>nd</sup> Edition, Blackwell Sciences 2002.
87. Bonert VH, **MELMED S**: Growth Hormone in The Pituitary 2<sup>nd</sup> Edition, Blackwell Sciences, 2002.
88. Bonert VH, **MELMED S**: Early Diagnosis and Treatment of Endocrine Disorders (Ed) Robert S. Bar, Humana Press Inc., 2002.
89. Ben-Shlomo A, **MELMED S**: Primary pharmacotherapy for acromegaly. The expanding role of octreotide II: advances in endocrinology and eye disease. Eds: Lamberts SWJ & Ghigo E. BioScientifica 2002.
90. Yu R, **MELMED S**: Pituitary oncogenes in Central and Peripheral mechanisms in pituitary disease (Eds DL Kleinberg and DR Clemmons) pp 99-118, BioScientifica Ltd, Bristol, 2002.
91. Castro AVB, **MELMED S**: Growth regulation: Clinical aspects of GHRH Encyclopedia of Hormones, Elsevier Science (USA), pp. 226-234, 2003.
92. Murray RD, **MELMED S**: Acromegaly in NORD Guide to Rare Disorders, Lippincott, Williams and Wilkins, Philadelphia, PA, 2003.
93. Murray RD, **MELMED S**: Growth Hormone Deficiency in NORD Guide to Rare Disorders, Lippincott, Williams and Wilkins, Philadelphia, PA, 2003.
94. **MELMED S**, Kleinberg DL: Anterior pituitary in Williams Textbook of Endocrinology 10<sup>th</sup> Edition, Larsen, Kronenberg, Melmed, Polonsky (Eds), Saunders Publication, pp. 177-280, 2003.
95. Murray RD, **MELMED S**: The Pituitary in Encyclopaedia of Life Sciences, 2004.
96. Heaney A, **MELMED S**: Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 2004.
97. Shimon I, **MELMED S**: Anterior pituitary hormones in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 2004.
98. Ben-Shlomo A, **MELMED S**: Acromegaly, Therapy. Encyclopedia of Endocrine Diseases Vol 1, 2004, Elsevier Inc.
99. **MELMED S**, Jameson JL: Disorders of the anterior pituitary and hypothalamus in 16<sup>th</sup> Edition of Harrison's Principles of Internal Medicine, Kasper, Braunwald, Fauci, Hauser, Longo, Jameson (Eds), McGraw Hill Publishing, pp 2076-2097, 2005.
100. **MELMED S**: Acromegaly in DeGroot Textbook of Endocrinology (5<sup>th</sup> Edition), 2005.
101. **MELMED S**. Evaluation of Pituitary Masses in De Groot Textbook of Endocrinology (5<sup>th</sup> Edition), 2005.
102. Heaney A, **MELMED S**: Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system. In Endocrinology: Basic and Clinical Principles, 2<sup>nd</sup> Edition (PM Conn and S Melmed, Eds), Humana Press, 2005.
103. Yu R, Hui H, **MELMED S**: Insulin secretion and action. In Endocrinology: Basic and Clinical Principles, 2<sup>nd</sup> Edition (PM Conn and S Melmed, Eds), Humana Press, 2005.
104. Donangelo I, **MELMED S**: Treatment of Acromegaly: Future. In Endocrine 2005, 28:123-8.
105. Donangelo I, **MELMED S**. Primary Medical Therapy of GH-Secreting Adenomas. In: Laws ER and Lanzino G: Transsphenoidal Surgery. Philadelphia, Elsevier, 2005.

106. Yu R, **MELMED S**: Pituitary tumor transforming gene: an update *in* Molecular Pathology of the Pituitary (Eds) Kontogeorgos G, Kovacs K. In Frontiers of Horm Res 32, pp. 175-185, 2006. Karger Publication.
107. **MELMED S**, Jameson JL: Disorders of the anterior pituitary and hypothalamus *in* Harrison's Endocrinology, J Larry Jameson (Ed), pp. 19-56, 2006.
108. Donangelo I, **MELMED S**: Molecular pathogenesis of pituitary adenomas *in* Clinical Endocrine Oncology, 2<sup>nd</sup> Edition, Ian Hay and John Wass (Eds), 2006.
109. Chesnokova V, Yu R, Ben-Shlomo A, **MELMED S**: Pituitary trophic status as a tumorigenic determinant in Hormonal Control of Cell Cycle, Melmed S, Rochefort H, Chanson P, Christen Y (Eds), Proceedings *in* International Workshop Fondation Ipsen, pp. 83-87, 2006.
110. **MELMED S** and Kleinberg D: Anterior Pituitary *in* Williams Textbook of Endocrinology 11<sup>th</sup> Edition, pp. 155-263, 2007.
111. **MELMED S**: Pituitary *in* ACP Medicine, Dale DC, Federman, DD (Eds). WebMD Corporation, 2008.
112. Ben-Shlomo A, **MELMED S**: Acromegaly *in* Endocrinology and Metabolism Clinics of North America, 37:101-122, 2008. PMID: PMC2697616
113. **MELMED S**, Jameson JL: Disorders of the Anterior Pituitary and Hypothalamus. 17<sup>th</sup> Edition of Harrison's Principles of Internal Medicine, Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo (Eds), McGraw Hill Publishing, 2195-2216, 2008.
114. Snyder P and **MELMED S**: Clinically nonfunctioning pituitary masses. In De Groot and Jameson Endocrinology, 6<sup>th</sup> Edition, by Elsevier Publication, 2009.
115. **MELMED S**: Acromegaly. In De Groot and Jameson Endocrinology, Elsevier Publication 6<sup>th</sup> Edition, 2009.
116. Yu R and **MELMED S**: Current concepts in molecular pathogenesis of acromegaly *in* Acromegaly: A handbook of history, current therapy and future prospects, JAH Wass (Eds), Bioscientifica Publishing, pp. 21-39, 2009.
117. Ben-Shlomo A, Liu NA, **MELMED S**: Pathogenesis of Cushing's Disease *in* Cushing's Disease Textbook, M. Bronstein (ed), 2009.
118. Donangelo I, **MELMED S**: Molecular pathogenesis of pituitary tumors. In Oxford Textbook of Endocrinology and Diabetes, Wass J & Stewart P (Eds), 2010.
119. Yu R, **MELMED S**: Pathogenesis of Pituitary Tumors. In Neuroendocrinology Textbook, Martini L (Ed), Elsevier Publisher, 2010.
120. **MELMED S**, Ho K: Pituitary Physiology and diagnostic evaluation. In Williams Textbook of Endocrinology, 12<sup>th</sup> Edition, Elsevier, 2010.
121. **MELMED S**, Kleinberg D: Pituitary masses and tumors. In Williams Textbook of Endocrinology, 12<sup>th</sup> Edition, Elsevier, 2010.
122. Bonert VH, **MELMED S**: Growth Hormone. In The Pituitary, 3<sup>rd</sup> Edition, Elsevier Publisher, San Diego, CA, 2010.
123. Ben-Shlomo A, **MELMED S**: Regulation of the hypothalamic pituitary axis. In The Pituitary, 3<sup>rd</sup> Edition, Elsevier Publisher, San Diego, CA, 2010.
124. **MELMED S**: Acromegaly. In The Pituitary, 3<sup>rd</sup> Edition, Elsevier, San Diego, CA, 2010.
125. Greenman Y, **MELMED S**: TSH-secreting pituitary tumors. In The Pituitary, 3<sup>rd</sup> Edition, Elsevier Publisher, San Diego, CA, 2010.
126. **MELMED S**, Jameson LJ: Disorders of the anterior pituitary and hypothalamus. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (Eds) *in* Harrison's Principles of Internal Medicine, 18<sup>th</sup> Edition 2010.
127. Chesnokova V, Zonis S, Ben-Shlomo A, Wawrowsky K, **MELMED S**: Molecular mechanisms of pituitary adenoma senescence. Arzt E, Bronstein M, Guitelman M (Eds) *in* Pituitary Today II: New Molecular, Physiological and Clinical Aspects, Front Horm Res, Basel, Karger 2010.
128. **MELMED S**: Pituitary Genetic factors in Cushings. New M, Lekarev O, Parsa A, Yuen TT, O'Malley B and Hammer GD (Eds) *in* Genetic Steroid Disorders, 2012.

129. Snyder PJ and **MELMED S**: Clinically non-functioning sellar masses. DeGroot LJ, Jameson JL, Kretser DD, Grossman AB, Marshall JC, Melmed S, Potts JT Jr, Weir GC (Eds) in Endocrinology: Adult and Pediatric, 7<sup>th</sup> Edition, Elsevier, 2013.
130. Parsa A, **MELMED S**: Genetic factors in Cushing Disease Pathogenesis. New MI (Ed), Lekarev O, Parsa A, Yuen TT, O'Malley B, Hammer GD (Assoc Eds) in Genetic Steroid Disorders, 2013, Elsevier.
131. **MELMED S** and Kleinberg D: Pituitary Masses and Tumors. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (Eds): in Williams Textbook of Endocrinology, 13th Edition, Elsevier, 2015.
132. **MELMED S**. Acromegaly. DeGroot LJ, Jameson JL, Kretser DD, Grossman AB, Marshall JC, Melmed S, Potts JT Jr, Weir GC (Eds) in Endocrinology: Adult and Pediatric, 7<sup>th</sup> Edition, Elsevier, 2015.
133. **MELMED S**, Jameson LJ: Hypopituitarism. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19<sup>th</sup> Edition, McGraw-Hill Publications, pp 2255-2261, 2015.
134. **MELMED S**, Jameson LJ: Anterior Pituitary Tumor Syndromes. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19<sup>th</sup> Edition, McGraw-Hill Publications, pp 2261-2274, 2015.
135. **MELMED S**, Jameson LJ: Anterior Pituitary: Physiology of Pituitary Hormones. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19<sup>th</sup> Edition, McGraw-Hill Publications, pp 401e1-401e4, 2015.